



Chemoenzymatic Synthesis and Fc γ Receptor Binding of Homogeneous Glycoforms of Antibody Fc Domain. Presence of a Bisecting Sugar Moiety Enhances the Affinity of Fc to Fc γ RIIIa Receptor

Guozhang Zou, Hirofumi Ochiai, Wei Huang, Qiang Yang, Cishan Li, and Lai-Xi Wang*

Institute of Human Virology and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States

 Supporting Information

ABSTRACT: Structurally well-defined IgG-Fc glycoforms are highly demanded for understanding the effects of glycosylation on an antibody's effector functions. We report in this paper chemoenzymatic synthesis and Fc γ receptor binding of an array of homogeneous IgG-Fc glycoforms. The chemoenzymatic approach consists of the chemical synthesis of defined *N*-glycan oxazolines as donor substrates, the expression of the Fc domain in a CHO cell line in the presence of an α -mannosidase inhibitor kifunensine, and an endoglycosidase-catalyzed glycosylation of the deglycosylated Fc domain (GlcNAc-Fc homodimer) with the synthetic glycan oxazolines. The enzyme from *Arthrobacter protophormiae* (Endo-A) was found to be remarkably efficient to take various modified *N*-glycan core oxazolines, including the bisecting sugar-containing derivatives, for Fc glycosylation remodeling, resulting in the formation of the corresponding homogeneous Fc glycoforms. Nevertheless, neither Endo-A nor the *Mucor hiemalis* endoglycosidase mutants (EndoM-N175A and EndoM-N175Q) were able to transfer full-length complex-type *N*-glycan to the Fc domain, implicating the limitations of these two enzymes in Fc glycosylation remodeling. Surface plasmon resonance (SPR) binding studies with the synthetic IgG-Fc glycoforms unambiguously proved that the presence of a bisecting GlcNAc moiety could significantly enhance the binding of Fc to Fc γ RIIIa, the activating Fc γ receptor, independent of Fc core-fucosylation. Interestingly, the Fc glycoforms carrying an unusual bisecting sugar moiety such as a mannose or a LacNAc moiety also demonstrated enhanced affinity to Fc γ RIIIa. On the other hand, the presence of a bisecting GlcNAc or core-fucosylation had little effect on the affinity of Fc to the inhibitory Fc γ receptor, Fc γ RIIb. Our experimental data also showed that the α -linked mannose residues in the pentasaccharide Man3GlcNAc2 core was essential to maintain a high affinity of Fc to both Fc γ RIIIa and Fc γ RIIb. The synthetic homogeneous Fc glycoforms thus provide a useful tool for elucidating how a fine Fc *N*-glycan structure precisely affects the function of the Fc domain.



INTRODUCTION

Monoclonal antibodies (MAbs) are a class of therapeutic glycoproteins used for the treatment of various human diseases including cancer and inflammatory disorders.^{1–3} Almost all the therapeutic monoclonal antibodies currently used for disease treatment are of the immunoglobulin G (IgG) type, which are composed of two light chains and two heavy chains that are associated to form three distinct protein domains linked by a flexible hinge region. The two identical Fab domains are specific for antigen binding, while the Fc domain, a homodimer consisting of the C_H2 and C_H3 subdomains, is engaged in the “downstream” effector functions of antibodies including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).^{2,4} ADCC and CDC effector functions are mediated by the interactions of the Fc domain with respective Fc γ receptors (such as Fc γ RIIIa and Fc γ RIIb) on effector cells and the C1q component of the complement cascade, respectively.⁴ The Fc homodimer carries two *N*-glycans at each of the conserved *N*-glycosylation sites (Asn-297) of the two C_H2 domains. Structural analysis has indicated that human

IgG-Fc *N*-glycans are typical biantennary complex-type *N*-glycans with considerable structural heterogeneity.^{5–7} More than 30 different Fc oligosaccharides were characterized, in which the core Asn-linked heptasaccharide GlcNAc2Man3GlcNAc2-Asn can be differentially decorated with core-fucosylation, bisecting GlcNAc attachment, and varied terminal galactosylation and sialylation (Figure 1).

Recent advances in glycobiology and immunology have suggested that antibody Fc glycosylation can significantly impact the structure and biological function of antibodies.^{2,8} It has been demonstrated that aglycosylated or deglycosylated IgG antibodies are almost completely devoid of Fc-mediated effector functions as a result of reduced or ablated binding to Fc γ receptors or those proteins in the complement system.^{7,9} Crystallographic studies and NMR analysis have shown that the Fc *N*-glycans have multiple noncovalent interactions with the Fc protein domain, implicating an important role of the *N*-glycan

Received: September 6, 2011

Published: October 17, 2011




Figure 1. Schematic presentations of the natural and synthetic human IgG1-Fc glycoforms. (A) Natural heterogeneous Fc glycoforms; (B) synthetic homogeneous Fc glycoforms. The IgG1-Fc structure was modeled on the basis of the crystal structure of an anti-HIV antibody, b12 (PDB code, 1hzh) (Saphire et al. *Science*, **2001**, 293, 1155). GlcNAc, N-acetylglucosamine; Man, mannose; Gal, galactose; Glc, glucose; Fuc, L-fucose; Sia, sialic acid. The dash lines represent variable decorations.

in maintaining an appropriate Fc domain conformations required for the specific interactions between Fc and Fc receptors for antibody's effector functions.^{6,9–16} It has been further demonstrated that the distinct fine structures of Fc N-glycans can define whether the antibody goes for activation (such as ADCC) or inhibitory (such as anti-inflammatory) effector functions.^{2,17} For example, core-fucosylation has been shown to significantly decrease the affinity of Fc to FcγIIIa receptor that correlates with the antibody's ADCC function and anticancer efficacy in vivo.^{18–22} On the other hand, specific terminal α-2,6-sialylation of IgG-Fc N-glycan, a minor population (about 5%) of the intravenous immunoglobulin (IVIg), has recently been demonstrated to be responsible for the anti-inflammatory activity of IVIg in the treatment of autoimmune diseases.^{4,23–25} As to the role of the bisecting GlcNAc residue in the Fc N-glycans, studies have shown that increasing the population of the bisecting GlcNAc contents leads to enhanced affinity to FcγIIIa receptor and thus enhanced ADCC function of the antibodies.^{21,26–28} However, another study has suggested that the lack of the core fucose, rather than the presence of a bisecting GlcNAc, plays the key role in enhancing the ADCC, as preaddition of the bisecting GlcNAc residue to the core-β-mannose inhibits core-fucosylation

in the biosynthetic pathway, resulting in an increased population of nonfucosylated glycoforms that demonstrate enhanced ADCC.¹⁹ It should be pointed out that many of the structure–activity relationship studies so far reported have used mixtures of Fc glycoforms, although some of the specific glycoforms were enriched by lectin affinity purification and/or enzymatic trimming. This situation sometimes makes a conclusive interpretation of the experimental results difficult.

The urgent need of various glycosylation-defined pure IgG-Fc glycoforms, which are difficult to isolate from natural sources, for structure–activity relationship studies and for biomedical applications has stimulated an intense interest in developing methods to control Fc glycosylation. These include glycan biosynthetic pathway engineering in plant, mammalian, and yeast expression systems to produce nonfucosylated IgG-Fc glycoforms with improved ADCC activity;^{26,29–33} sequential enzymatic trimming of Fc N-glycans to produce truncated IgG-Fc glycoforms for structural analysis and Fcγ receptor binding studies;^{13,28,34} and chemoselective Fc glycosylation by site-directed mutagenesis at the glycosylation site (N297C) followed by chemoselective ligation with a glycan.³⁵ We have previously described a convergent chemoenzymatic method for IgG-Fc glycosylation remodeling




Figure 2. Structures of synthetic sugar oxazolines.

that takes advantage of the transglycosylation activity of the *Arthrobacter* endoglycosidase (Endo-A) and the highly active *N*-glycan oxazoline as the donor substrates.³⁶ In this approach, an IgG-Fc was first expressed in yeast to give the IgG-Fc carrying yeast *N*-glycans at the Fc domain. Then the heterogeneous *N*-glycans were cleaved to leave only the innermost GlcNAc attached at the glycosylation site (Asn-297). Finally a defined core *N*-glycan was transferred to the GlcNAc moiety by Endo-A to provide a homogeneous IgG-Fc glycoform. This enzymatic transglycosylation approach preserves the natural *N*-glycan core structure in the Fc domain, which appears essential for the effector functions of antibodies.² Our initial studies have suggested that the enzymatic transglycosylation was feasible for glycosylation remodeling of recombinant IgG-Fc dimers under mild conditions without the need of denaturing the Fc protein domain.³⁶ Despite this initial success, it is still to be demonstrated whether different types of *N*-glycans can be introduced at the Fc domain by this method. Glycosylation remodeling of the IgG-Fc homodimer could be particularly challenging as the two Fc *N*-glycans at the glycosylation sites (Asn-297) are sandwiched between the two Fc domains, which might be less accessible for enzymatic reactions.^{9–15} Our initial success in the chemoenzymatic glycosylation remodeling of IgG-Fc,³⁶ together with recent advances in the method development,^{37–48} prompted us to expand the chemoenzymatic approach to the synthesis of various homogeneous IgG-Fc glycoforms while examining the scope and limitations of the endoglycosidase-catalyzed transglycosylation for IgG-Fc glycosylation remodeling. We report in this paper the chemoenzymatic synthesis of an array of specific, homogeneous IgG-Fc glycoforms (Figure 1, glycoforms Fc-1 to Fc-6), with a focus on elucidating the roles of individual sugar residues within and/or flanking the Fc *N*-glycan core in the binding to Fc γ receptors Fc γ RIIIa and Fc γ RIIb. In particular, several bisecting sugar-containing Fc glycoforms, including the unusual bisecting LacNAc Fc glycoform that was recently discovered as a minor IgG-Fc glycoform with unknown function,⁴⁹ were synthesized. Our experimental data indicate that Endo-A is remarkably efficient to take various modified *N*-glycan core oxazolines, including the bisecting sugar-containing derivatives, for Fc glycosylation remodeling. Nevertheless, neither Endo-A nor the *Mucor hiemalis* endoglycosidase mutant (EndoM-N175A and EndoM-N175Q) was able to transfer full-length complex-type *N*-glycan oxazoline to the Fc domain, implicating the limitations


of these two enzymes in Fc glycosylation remodeling. Our surface plasmon resonance (SPR) binding studies with well-defined synthetic IgG-Fc glycoforms provide unambiguous evidence indicating that the presence of a bisecting GlcNAc moiety could directly enhance the interaction between Fc to Fc γ RIIIa, independent of core-fucosylation, whereas the presence of a bisecting GlcNAc has little effect on the affinity of Fc to Fc γ RIIb. Our experimental data also showed that the two α -linked mannose residues in the pentasaccharide Man3GlcNAc2 core is essential to maintain a high affinity of Fc to the Fc γ RIIIa, while the core- β -mannose residue could be changed to a β -glucose moiety without significantly affecting the binding to Fc γ RIIIa.

RESULTS AND DISCUSSION

Synthesis of Bisecting GlcNAc-Containing *N*-Glycan Oxazoline (1) and Bisecting LacNAc-Containing *N*-Glycan Oxazoline (2). Chemoenzymatic synthesis of the homogeneous Fc glycoforms by the endoglycosidase-catalyzed transglycosylation requires the preparation of the corresponding *N*-glycan oxazolines as donor substrates. The structures of sugar oxazolines synthesized and used for the present study are listed in Figure 2. These glycan oxazolines were designed for the preparation of the well-defined homogeneous Fc glycoforms that will allow a detailed probing of the effects of varied glycan structures on the binding of Fc to respective Fc γ receptors that are essential for antibody effector functions. Chemical synthesis of bisecting GlcNAc-containing *N*-glycans of varied size has been reported by several research groups.^{50–55} These studies suggested that the 4-hydroxyl group of the core- β -mannose was sterically hindered and made difficult to glycosylate when the 3- and 6-positions of the core- β -mannose were preoccupied with bulky sugar residues. Thus, for the synthesis of the bisecting GlcNAc-containing sugar oxazoline (1), we adopted a synthetic strategy of introducing the bisecting GlcNAc residue prior to the glycosylation at the 3- and 6-positions of the β -mannose moiety (Scheme 1).

Glycosylation of monosaccharide **7**⁵⁶ with thioglycoside donor **8**⁵⁷ under the promotion of 1-benzenesulfinyl piperidine (BSP)/2,4,6-tri-*tert*-butylpyrimidine (TTBP)/trifluoromethanesulfonic anhydride (Tf₂O)⁵⁶ gave the corresponding disaccharide product ($\beta/\alpha = 6:1$), from which the desired β -isomer **9** was isolated in 56% yield. Removal of the benzylidene group by mild acidic hydrolysis provided diol **10** in 80% yield. The primary


Scheme 1. Synthesis of Bisecting GlcNAc- and LacNAc-Containing *N*-Glycan Oxazolines^a



^a Reagents and conditions: (a) BSP, TBP, Tf₂O, CH₂Cl₂, 56%. (b) 80% aq. AcOH, 80%. (c) TBDMSCl, pyridine, 95%. (d) BF₃·OEt₂, CH₂Cl₂, 76%. (e) TFA, CH₂Cl₂, 88%. (f) TMSOTf, CH₂Cl₂, 54%. (g) (1) NH₂NH₂ monohydrate, EtOH, H₂O; (2) Ac₂O, pyridine, 77% (2 steps). (h) (1) Pd(OH)₂-C, H₂, CH₂Cl₂, MeOH; (2) Ac₂O, pyridine, 89% (2 steps). (i) TMSBr, BF₃·OEt₂, 2,4,6-collidine, CH₂Cl₂, 48%. (j) MeONa, MeOH, quantitative. (k) MeONa, MeOH, quantitative. (l) DMC, Et₃N, H₂O, quantitative. (m) UDP-Gal, β-1,4-galactosyltransferase, buffer, quantitative. (n) DMC, Et₃N, H₂O, quantitative.

hydroxyl group was then selectively protected with TBDMSCl in pyridine to give disaccharide **11** in excellent yield. $\text{BF}_3 \cdot \text{Et}_2\text{O}$ -catalyzed glycosylation of the 4-OH with glucosamine building block **12**⁵⁸ gave the trisaccharide **13** in 76% yield, in which the bisecting glucosamine moiety was introduced with a complete β -selectivity. The TBDMS and PMB groups in trisaccharide **13** were simultaneously removed by treatment with TFA in CH_2Cl_2 to give diol **14** in 88% yield. Diglycosylation of **14** was achieved with an excess of glycosyl donor **15** under the catalysis of TMSOTf, giving pentasaccharide **16** in 54% yield. The phthalimido groups were then changed to the acetamido groups in two steps by treatment with hydrazine hydrate followed by acetylation with Ac_2O /pyridine to afford **17**, which was subject to catalytic hydrogenation and subsequent O-acetylation to give the peracetate (**18**) in 89% yield. Initial attempts to form the sugar oxazoline by the Lewis acid-catalyzed reaction using $\text{TMSBr}/\text{BF}_3 \cdot \text{Et}_2\text{O}/2,4,6\text{-collidine}$ as the promoter^{59,60} gave only a moderate

yield (48%) of **19**, mainly due to decomposition of the oligosaccharide under the acidic reaction conditions. De-O-acetylation of **19** with a catalytic amount of MeONa in MeOH provided pentasaccharide oxazoline **1**. Recently, a method for one-step conversion of unprotected *N*-acetyl-2-amino sugars to sugar oxazolines using a chloroformamidinium reagent in water was reported,⁶¹ and we have also shown that this method was equally efficient for making even very large complex *N*-glycan oxazolines from free *N*-glycans.⁴¹ Thus, we tested this method for preparing oxazoline **1** from free pentasaccharide **20**, which was obtained by de-O-acetylation of **18**. Treatment of **20** with an excess of 2-chloro-1,3-dimethylimidazolium chloride (DMC) and Et₃N in water afforded the desired sugar oxazoline **1** in quantitative yield, which was readily purified by gel filtration on a Sephadex G-10 column. These results clearly indicate that the one-step conversion of free glycan to the sugar oxazoline in an aqueous solution is much more efficient than the Lewis acid-catalyzed oxazoline ring

Scheme 2. Synthesis of a Glucose-Containing *N*-Glycan Oxazoline^a

^a Reagents and conditions: (a) NIS, TfOH, dichloroethane, 63%. (b) DDQ, CH₂Cl₂, H₂O, 87%. (c) Et₃SiH, PhBCl₂, CH₂Cl₂, 94%. (d) TMSOTf, CH₂Cl₂, 95%. (e) AcSH, pyridine, CHCl₃, 78%. (f) 1) MeONa, MeOH, then Dowex (H⁺); 2) Pd(OH)₂/C, H₂, MeOH; 3) Ac₂O, pyridine, 92% (three steps). (g) 1) MeONa, MeOH, then Dowex (H⁺); 2) DMC, Et₃N, H₂O, 95% (two steps).

formation from the O-acetylated derivative. The synthesis of the bisecting LacNAc-containing sugar oxazoline (**2**) started with enzymatic extension of the sugar chain in tetrasaccharide **20**. We found that addition of a β -1,4-linked galactose to the bisecting GlcNAc could be readily achieved by incubation of **20** with UDP-Gal and a β -1,4-galactosyltransferase from bovine milk in a phosphate buffer, giving hexasaccharide **21** in quantitative yield. Compound **21** was then converted into hexasaccharide oxazoline **2** in a single step upon treatment with an excess of DMC and Et₃N (Scheme 1). The bisecting mannose-containing oxazoline, Man4GlcNAc-oxazoline (**3**), was synthesized following the previously reported procedure.⁴⁵

Synthesis of Core-Glucose-Containing Glycan Oxazoline (4). Another sugar oxazoline that would be interesting for structure–activity relationship studies related to Fc glycosylation is the tetrasaccharide oxazoline (**4**), in which the core- β -mannose moiety was replaced with a glucose moiety. Oxazoline **4** was previously synthesized by Fairbanks and co-workers and was shown to be a substrate for Endo-A.⁴⁶ We describe here an alternative synthesis of **4** (Scheme 2). Briefly, coupling of thioglycoside **22**⁶² and acceptor **23**⁵⁶ gave the β -linked disaccharide **24**. the PMB group was selectively removed by DDQ to provide **25**, which was then converted to diol **26** in 94% yield by regioselective reductive ring-opening of the benzylidene group using Et₃SiH/PhBCl₂ in CH₂Cl₂. Glycosylation of **26** with glycosyl donor **27** under the catalysis of TMSOTf, with simultaneous introduction of two mannose residues, afforded tetrasaccharide **28** in 95% yield. A one-step transformation of the azido group to an acetamido group was carried out by treatment of **28** with AcSH in pyridine to give **29** (78% yield), which was then converted into the peracetate derivative (**30**) by sequential de-O-acylation, catalytic hydrogenation, and O-acetylation. Finally, compound **30** was de-O-acetylated and the resulting free oligosaccharide was converted to sugar oxazoline **4** in excellent yield through the single-step, DMC-promoted oxazoline-forming reaction (Scheme 2).

The synthesis of Man3GlcNAc-oxazoline (**5**) and ManGlcNAc-oxazoline (**6**) was previously reported.⁶⁰

Expression of Human IgG1-Fc Homodimer Carrying a Homogeneous Man9GlcNAc2 Glycan at Each of the Fc Glycosylation Sites (Asn-297). We have previously expressed human IgG1-Fc in yeast *Pichia pastoris* to obtain a recombinant IgG1-Fc carrying yeast *N*-glycans.³⁶ The *N*-glycans were a mixture of yeast high-mannose type glycans ranging from Man9GlcNAc2 to Man13GlcNAc2. To obtain a homogeneous, human-like Man9GlcNAc2 glycoform of the Fc domain, we expressed human IgG1-Fc in Chinese hamster ovary (CHO) cell lines in the presence of kifunensine, a potent class I α -mannosidase inhibitor that blocks further processing of the Man9GlcNAc2 *N*-glycan during glycoprotein biosynthesis.^{63–65} It has been previously reported that expression of a monoclonal antibody in CHO or human HEK293 cell lines in the presence of kifunensine could efficiently control the *N*-glycosylation at the high-mannose type stage.^{11,66} Recently we have successfully overproduced Man9GlcNAc2-glycoform of Fc-fused HIV-1 V3 domain using kifunensine as the α -mannosidase inhibitor.⁶⁷ Following this protocol, we overproduced human IgG1-Fc in CHO cell lines in the presence of kifunensine (2 μ g/mL). The recombinant Fc was purified by protein A affinity chromatography. SDS-PAGE analysis indicated that the recombinant Fc expressed in the presence of kifunensine appeared as a single band of a size of \sim 65 kDa and \sim 33 kDa under nonreducing and reducing conditions, respectively (Figure 3A, lanes 1 and 2). This result suggests that the recombinant IgG1-Fc was produced as a homodimer. Treatment of the IgG1-Fc with peptide:*N*-glycosidase F (PNGase F), which would completely deglycosylate the glycoprotein by hydrolyzing the glycosylamide linkage between *N*-glycan and the Asn residue, gave a new single band that was about 2 kDa less than the glycosylated monomeric IgG1-Fc (Figure 3A, lane 3, shown under reducing SDS-PAGE conditions). These results implicate the attachment of two *N*-glycans





Figure 3. SDS-PAGE and MALDI-TOF MS analysis of recombinant IgG1-Fc. (A) SDS-PAGE: Lane M, protein marker; lane 1, HM-Fc (nonreducing conditions); lane 2, HM-Fc, reducing conditions; lane 3, PNGase F-treatment of HM-Fc; (B) MALDI-TOF MS of HM-Fc; (C) MALDI-TOF MS of *N*-glycans released from HM-Fc; (D) MALDI-TOF MS of *N*-glycans released from CHO-expressed Fc (CT-Fc).

Scheme 3. Chemoenzymatic Synthesis of Homogeneous Glycoforms of Human IgG1-Fc^a



^a Reagents and conditions. The high-mannose IgG1-Fc glycoform was produced in CHO cells in the presence of kifunensine. Then the high-mannose *N*-glycan was removed by Endo-H to give the GlcNAc-containing IgG1-Fc, which served as an acceptor for the Endo-A-catalyzed transglycosylation with respective synthetic sugar oxazolines (1 to 6) to afford the corresponding homogeneous IgG1-Fc glycoforms.

in the HM-Fc homodimer. The recombinant HM-Fc was also characterized by direct MALDI-TOF MS analysis of the Fc homodimer, which gave a species with an average *m/z* of 65447 (Figure 3B). The experimental data was in good agreement with the theoretical molecular weight ($M = 65444$ Da) of Fc homodimer carrying two high-mannose type (Man₉GlcNAc₂) *N*-glycans, which was calculated on the basis of the amino acid sequence of the recombinant Fc plus two Man₉GlcNAc₂ glycans (Figure S1, Supporting Information). The *N*-glycans in the recombinant IgG1-Fc was further verified by MALDI-TOF MS analysis. The MS spectrum of the PNGase F-released *N*-glycans indicated that more than 90% of the *N*-glycans attached were Man₉GlcNAc₂, with Man₈GlcNAc₂ being a minor fraction (Figure 3C). In contrast, the *N*-glycans released from the wild-type recombinant IgG1-Fc produced in CHO cell lines in the absence of kifunensine, designated as CT-Fc, were a mixture of biantennary complex-type *N*-glycans that were fucosylated and

contained 0, 1, and 2 terminal galactose residues, respectively (designated as G0F, G1F, and G2F glycoforms) (Figure 3D).

Synthesis of IgG-Fc Homogeneous Glycoforms through Chemoenzymatic Glycosylation Remodeling. Our preliminary studies have shown that the Endo-A-catalyzed transglycosylation with Man₃GlcNAc oxazoline (5) could be efficiently applied to the seemingly hindered GlcNAc residues of the Fc homodimer (GlcNAc-Fc) to make a homogeneous glycoform of IgG-Fc under very mild conditions, without the need of denaturing the Fc domain. Thus, the native structure of IgG1-Fc homodimer was kept intact during the enzymatic deglycosylation and subsequent enzymatic transglycosylation.³⁶ In the present work, we used the high-mannose type IgG-Fc homodimer (HM-Fc) that was expressed in CHO cell line in the presence of kifunensine as the starting material for glycosylation remodeling to prepare a panel of new homogeneous IgG-Fc glycoforms, as shown in Scheme 3. Treatment of HM-Fc with Endo-H under




Figure 4. SDS-PAGE and MALDI-TOF MS analysis of GlcNAc-Fc and transglycosylation product Fc-1. A, SDS-PAGE: Lane 1, HM-Fc; lane 2, GlcNAc-Fc; lane 3, transglycosylation product Fc-1; lane 4, PNGase F-treatment of Fc-1; B, MALDI-TOF MS of GlcNAc-Fc; C, MALDI-TOF MS of product Fc-1; D, MALDI-TOF MS of *N*-glycans released from Fc-1.

mild conditions (phosphate buffer, pH 6.5, 23 °C) led to an efficient conversion of HM-Fc (Figure 4A lane 1) to the GlcNAc-Fc (Figure 4A, lane 2). The identity of the GlcNAc-Fc homodimer was confirmed by its MALDI-TOF MS (Calculated, $M = 62119$ Da; found (m/z), 62122) (Figure 4B). We first examined the Endo-A-catalyzed reaction of bisecting GlcNAc oxazoline **1** and the GlcNAc-Fc homodimer (donor/acceptor, 20:1, molar ratio; 10 mol equiv to each GlcNAc moiety of the homodimer) in a phosphate buffer (pH 7.0), and monitored the reaction by SDS-PAGE. We found that the bisecting GlcNAc-containing oxazoline (**1**) was an excellent substrate for Endo-A and the transglycosylation reaction went smoothly to give a product, which appeared as a new band that was about 1 kDa larger than the GlcNAc-Fc under reducing SDS-PAGE conditions (Figure 4A, lane 3 vs lane 2). After 3 h, all the GlcNAc-Fc was converted to the new product. The single band for the glycosylated IgG-Fc under the reducing conditions suggests that both the glycosylation sites in the Fc homodimer were glycosylated. (The Fc homodimer would be reduced to monomeric Fc on SDS-PAGE in the presence of 2-mercaptoethanol. If any one of the two glycosylation sites were not transglycosylated, it would show up as the monomeric GlcNAc-Fc in SDS-PAGE.) The product, Fc-1, was readily purified by affinity chromatography on a protein A column. Treatment of glycoform Fc-1 with PNGase F led to the removal of the *N*-glycans, giving a single band that was about 1 kDa smaller than the Fc-1 under reducing conditions (Figure 4A, lane 4 vs lane 3). Since PNGase F specifically hydrolyzes the amide linkage between the *N*-glycan and the Asn residue in the protein, the result suggests that the transferred glycans were specifically attached to the GlcNAc moieties in the GlcNAc-Fc homodimer to form an intact *N*-glycan in the product, rather than on any other amino acid residues. MALDI-TOF MS spectrum (Figure 4C) of the Fc-1 showed a single species (m/z) at 63909, which matched well with the expected molecular mass (63905 Da) of the Fc homodimer carrying two bisecting-GlcNAc-Man3GlcNAc2 glycans. Further characterization of the product was performed by analysis of the attached *N*-glycans. The *N*-glycans were first released by PNGase F and were then analyzed by MALDI-TOF MS: calculated for GlcNAc-Man3GlcNAc2, $M = 1113.41$ Da; Found (m/z), 1136.80 [$M + Na$]⁺ (Figure 4D). It should be noted that we have previously demonstrated that terminal GlcNAc in an *N*-glycan was itself eligible to serve as an acceptor for enzymatic transglycosylation.^{42,68} In the present case, we did not observe cross-transglycosylation to the bisecting GlcNAc moiety under the transglycosylation conditions used (5 mM sugar oxazoline, 0.5 mM GlcNAc-Fc). This result suggests that the bisecting GlcNAc

moiety might be relatively hindered in comparison with the terminal GlcNAc on the $\alpha 1,3$ - and $\alpha 1,6$ - arms of the *N*-glycan core.⁴² Nevertheless, we did observe self-condensation of the bisecting GlcNAc-containing Man3GlcNAc-oxazoline (**1**) when a much higher concentration (50 mM) of the sugar oxazoline (**1**) alone was incubated with a larger amount of Endo-A, leading to the formation of a series of novel oligomers (data not shown). A more detailed study on this self-condensation reaction of the sugar oxazoline will be described elsewhere.

Transglycosylation of GlcNAc-Fc with the bisecting LacNAc-containing glycan oxazoline (**2**) was performed in the similar way as for the preparation of the bisecting GlcNAc glycoform (Fc-1). It was found that the bisecting LacNAc-containing glycan oxazoline (**2**) was also an excellent substrate for Endo-A, leading to the formation of another Fc glycoform, Fc-2. Again, when an excess of sugar oxazoline was used (10-fold molar excess for each GlcNAc acceptor in the GlcNAc-Fc homodimer), the transglycosylation could go to completion and the product (Fc-2) was readily purified by Protein A affinity chromatography. The identity of glycoform Fc-2 was characterized by MALDI-TOF MS analysis of both the intact glycoprotein and the *N*-glycan released by PNGase F treatment: MALDI-TOF MS of Fc-2, Calculated for Fc-2, $M = 64229$ Da; found (m/z), 64222. MALDI-TOF MS of the attached *N*-glycan, calculated for LacNAc-Man3GlcNAc2, $M = 1275.46$ Da; found (m/z), 1298.40 [$M + Na$]⁺. The Endo-A-catalyzed transglycosylation of GlcNAc-Fc with the other sugar oxazolines, including Man4-GlcNAc-oxazoline (**3**), Man2GlcGlcNAc-oxazoline (**4**), Man3-GlcNAc-oxazoline (**5**),⁵⁸ and ManGlcNAc-oxazoline (**6**),⁶⁰ was performed in a similar way to give the corresponding glycoforms, Fc-3 to Fc-6, respectively (Scheme 3). Except for the enzymatic reaction with the disaccharide oxazoline (**6**), which was much slower than the reaction with sugar oxazoline **1**, all the enzymatic transglycosylations gave the corresponding products efficiently. In the case of disaccharide oxazoline **6**, more sugar oxazoline (15-fold molar excess for each GlcNAc residue in the GlcNAc-Fc homodimer) was added to push the transglycosylation to completion. Again, the Fc glycosylation products were purified by protein A affinity chromatography and characterized by MALDI-TOF MS of the intact glycoprotein as well as the *N*-glycans released (see Experimental Section).

We also attempted to make a homogeneous Fc glycoform carrying a full-length biantennary complex-type *N*-glycan. Endo-A is an endoglycosidase specific for the hydrolysis and transglycosylation of high-mannose type *N*-glycans, but we have recently found that Endo-A also possesses a low activity on complex-type *N*-glycan oxazoline for transglycosylation without product












Figure 5. SPR sensorgrams of the binding of various Fc glycoforms to Fc γ RIIIa receptor from a representative experiment. Fc glycoforms were immobilized by Protein A capture, and the binding was analyzed by injecting the respective Fc γ receptors at varied concentrations.

hydrolysis when a large amount of Endo-A and a high concentration of substrates were used.⁴¹ Thus, we tested the ability of Endo-A to glycosylate GlcNAc-Fc using a complex type of glycan oxazoline as the donor substrate (see Figure S2, Supporting Information [SI]). SDS-PAGE analysis of the reaction mixture after 3 h incubation did not indicate the formation of a transglycosylation product (SI, Figure S2, lane 3). This result suggests that, although Endo-A is efficient to make various Fc glycoforms carrying the core *N*-glycans, its activity is not sufficient to transfer the full-length complex-type *N*-glycan to GlcNAc-Fc domain. We then tested the mutants of the fungus enzyme, EndoM-N175A and EndoM-175Q. We have previously reported that the two glycosynthase mutants were able to transfer complex-type glycan oxazolines to GlcNAc-ribonuclease and GlcNAc-peptides, using the corresponding sugar oxazoline (CT-oxazoline) as the donor substrate.^{38,43,44,69} When the CT-oxazoline and GlcNAc-Fc were incubated with EndoM-N175A, SDS-PAGE analysis did not reveal the formation of any transglycosylation product (SI, Figure S2, lane 4). Under the same reaction conditions, the EndoM-N175Q mutant did not glycosylate the GlcNAc-Fc either (data not shown). Surprisingly, Endo-M (either the wild-type or the mutants, N175A or N175Q) also failed to transfer the simple Man3GlcNAc-oxazoline to GlcNAc-Fc. Given the fact that EndoM-N175A and EndoM-N175Q could efficiently transfer the complex-type sugar oxazoline and simple Man3GlcNAc-oxazoline to GlcNAc-peptides and even GlcNAc-containing ribonuclease B,^{38,43,44,69} the present results suggest that the active site of Endo-M enzyme

might not be able to access to the GlcNAc moiety in acceptor GlcNAc-Fc, which was sandwiched by the two Fc domains and could be sterically hindered. As Endo-A could efficient transfer various core-modified *N*-glycan oxazolines to GlcNAc-Fc, the failure of Endo-A to transfer complex-type glycan oxazoline might simply reflect the intrinsic low activity of Endo-A on complex-type *N*-glycans, rather than its recognition to acceptor GlcNAc-Fc. These results indicate the difference in acceptor substrate flexibility for the two endoglycosidases (Endo-A and Endo-M). We are currently working on site-directed mutagenesis of Endo-A and are also testing other endoglycosidases in order to find an enzyme or mutants capable of effectively attaching full-length complex-type *N*-glycans to IgG-Fc to make homogeneous complex-type IgG-Fc glycoforms.

Binding of IgG-Fc Glycoforms with the Stimulatory Fc γ Receptor (Fc γ RIIIa) and the Inhibitory Fc γ Receptor (Fc γ RIIb). With the recombinant and synthetic Fc glycoforms in hands, we evaluated their affinity to Fc γ receptors Fc γ RIIIa and Fc γ RIIb using SPR technology. In our previous study,³⁶ we directly immobilized Fc γ RIIIa on the chips and flowed different IgG-Fc glycoforms at varied concentrations. While the direct “random” immobilization provided a quick comparison of the binding of different Fc glycoforms when the same chip was used, the affinity as measured by the apparent K_D values (found at μ M concentrations for the interaction between wild-type IgG-Fc and Fc γ RIIIa) seemed to be significantly underestimated, probably due to partial denaturing of the receptor structure during random immobilization. In the present study, we measured the affinity by

Table 1. Binding Affinities of IgG-Fc Glycoforms to Fc γ Receptors Fc γ RIIIa and Fc γ RIIb^a

IgG-Fc glycoforms		Fc γ RIIIa		Fc γ RIIb	
Name	N-glycan attached	K _D (nM)	Relative Affinity ^{b)}	K _D (μ M)	Relative Affinity ^{b)}
CT-Fc	Complex type	136.4 \pm 3.1	1	2.10 \pm 0.12	1
HM-Fc		45.0 \pm 1.7	3.1	3.5 \pm 0.17	0.60
Fc-1		22.0 \pm 2.1	6.2	2.20 \pm 0.15	0.95
Fc-2		40.7 \pm 2.5	3.4	N.D. ^{c)}	-
Fc-3		46.8 \pm 1.2	2.9	2.52 \pm 0.20	0.83
Fc-4		78.5 \pm 2.4	1.7	N.D. ^{c)}	-
Fc-5		58.4 \pm 0.6	2.3	2.90 \pm 0.22	0.72
Fc-6		354 \pm 11	0.4	>10	-
GlcNAc-Fc		>3000	<0.05	>10	-

^a The affinity was measured on a BIAcore T100, and the K_D values were calculated using an equilibrium binding model by fitting the SPR data. ^{b)} The K_D data (mean \pm S.D.) were obtained from a set of two independent experiments. ^{c)} Relative affinity was calculated as K_D (natural complex-type Fc)/K_D (variant Fc glycoforms). ^{d)} Not determined.

site-specific immobilization of individual Fc glycoforms through their affinity capture with preimmobilized protein A on the chips, as demonstrated in previous reports for site-specific immobilization of monoclonal antibodies.^{34,70} The Fc γ receptors at various concentrations were injected as analytes. A typical SPR profile for the interactions between Fc glycoforms and the Fc γ RIIIa is shown in Figure 5. The K_D values for the binding of the various Fc glycoforms to Fc γ receptors Fc γ RIIIa and Fc γ RIIb, which were obtained by fitting the binding data with a 1:1 steady-state binding model using BIAcore T100 evaluation software, are listed in Table 1. We found that the site-directed immobilization of the Fc glycoforms by affinity capture provided an accurate and highly reproducible measurement of the affinity of Fc glycoforms to Fc γ receptors, as it provides a consistent surface orientation of the immobilized proteins from experiment to experiment. The protein A chips could be easily regenerated and reused for capturing and measuring different Fc glycoforms. It should be pointed out that protein A binding (capture) would not interfere with the interaction between Fc domain and Fc γ receptors, as the protein A binds the C_H2/C_H3 interface of the Fc domain, while the Fc γ receptors' binding sites locate presumably at the interface of the low hinge region and the up C_H2 domain.⁷¹

Using the K_D as an estimate of the relative affinity, we found that the simple GlcNAcMan3GlcNAc2-Fc glycoform (Fc-1) carrying a bisecting GlcNAc moiety had the highest affinity for Fc γ RIIIa (K_D = 22 nM). This is about 6-fold as high as that of the wild-type IgG-Fc (CT-Fc) carrying the fucosylated complex-type N-glycans (K_D = 136 nM), 2-fold as high as that of the Man9GlcNAc2 glycoform (HM-Fc) (K_D = 45 nM), and about 3-fold as high as that of the Man3GlcNAc2-glycoform

(Fc-5, K_D = 58 nM) (Table 1). Interestingly, the Fc glycoforms with an unnatural bisecting LacNAc moiety (Fc-2) (K_D = 41 nM) or a mannose moiety (Fc-3) (K_D = 47 nM) also showed enhanced affinity in comparison with the Man3GlcNAc2 Fc-glycoform (Fc-5, K_D = 58 nM), although the enhancement is less significant than the addition of the natural bisecting GlcNAc moiety. These results indicate that adding a bisecting sugar moiety to the core N-glycan could enhance the affinity of Fc domain to Fc γ RIIIa receptor, but the enhancement depends on the nature of the sugar moiety inserted. Trimming the high-mannose structure from Man9GlcNAc2 down to the pentasaccharide core-Man3-GlcNAc2 only slightly decreased the affinity (Man9-Fc, K_D = 45 nM; Fc-5, K_D = 58 nM). However, removal of the two outer mannose residues from the Man3GlcNAc2 core to the Man-GlcNAc2 glycoform (Fc-6, K_D = 354 nM) resulted in about a 6-fold drop of the Fc affinity to Fc γ RIIIa. Further trimming of the oligosaccharide down to the glycoform (GlcNAc-Fc, K_D > 3000 nM), which carries only the innermost GlcNAc moiety, resulted in dramatic loss of the Fc affinity. These results clearly indicate the essential role of the pentasaccharide core at the Fc domain for its high affinity binding to Fc γ RIIIa. On the other hand, changing the core- β -mannose moiety in the Man3GlcNAc2-glycoform (Fc-5, K_D = 58 nM) to a glucose moiety such as the Man2-GlcNAc2-glycoform (Fc-4, K_D = 79 nM) did not have significant effect on the Fc affinity, suggesting that the C-2 configuration of the core- β -mannose moiety in the Fc N-glycan is not critical for Fc recognition of Fc γ RIIIa. Taken together, our experimental data clearly indicate that the Fc domain affinity to Fc γ RIIIa could be precisely tuned by the fine structures of the Fc N-glycan. Our experimental data with the pure, homogeneous

synthetic Fc glycoforms provided unambiguous evidence showing that the presence of a bisecting GlcNAc moiety on the Fc glycan core could directly enhance the binding of Fc to Fc γ RIIIa. This result clarifies a long-standing controversial problem in the field as to the role of bisecting GlcNAc.^{19,21,26–28} The bisecting GlcNAc moiety plays both a direct and an indirect role in enhancing antibody Fc affinity to Fc γ RIIIa. On one hand, the presence of a bisecting GlcNAc moiety can directly impact the Fc affinity to Fc γ RIIIa, independent of core-fucosylation. On the other hand, preaddition of a bisecting moiety to the *N*-glycan core can inhibit the enzymatic attachment of a core-fucose moiety during biosynthesis, playing an indirect role in enhancing the affinity of Fc to Fc γ RIIIa resulting from reduced population of the nonfucosylated Fc glycoforms.

We also measured the affinity of selected Fc glycoforms to the inhibitory Fc γ receptor Fc γ RIIb. Fc γ RIIb is an important regulator of both adaptive and innate immunity.⁴ We found that the Fc glycoforms with or without the bisecting sugar moiety (comparing Fc-1, Fc-2, and Fc-3 to Fc-5) showed similar affinity to Fc γ RIIb ($K_D = 2–3\ \mu\text{M}$) (Table 1). Thus, in contrast to the observation that addition of a bisecting GlcNAc moiety significantly enhanced Fc affinity to the activating receptor (Fc γ RIIIa), the presence of a bisecting sugar moiety had little effect on the affinity to the inhibitory Fc γ receptor. The similar binding affinity of the Fc glycoform carrying the core-fucosylated *N*-glycan (CT-Fc) to those without a core fucose moiety (HM-Fc, Fc-1, Fc-2, Fc-3, and Fc-5) also indicated that the presence of a core fucose moiety in the *N*-glycan did not have much influence on the binding of Fc to Fc γ RIIb. However, when the Fc *N*-glycan was trimmed off to leave only the trisaccharide ManGlcNAc2 core or the innermost GlcNAc moiety (Fc-6 and GlcNAc-Fc), the binding of the Fc domain to Fc γ RIIb became very weak, for which we did not obtain an accurate K_D value. This observation is consistent with the previously reported observation on Fc γ RIIb-binding of core-fucosylated and truncated IgG-Fc glycoforms.³⁴ Thus, it seems that the pentasaccharide (Man3GlcNAc2) core of the Fc *N*-glycan is essential and sufficient for the binding of Fc domain to Fc γ RIIb, but further decoration such as addition of a bisecting GlcNAc moiety to the core has little effect on the affinity.

Identification of high-affinity Fc γ RIIIa-binding glycoforms with enhanced ADCC function is clinically significant to address the issue of Fc γ receptor polymorphism found in cancer patients who are less or not responsive to the treatment with common MAbs. In these patients, the Fc γ RIIIa-F158 allele has low affinity to therapeutic antibody such as rituximab in comparison with the high-affinity receptor Fc γ RIIIa-V158 allele.^{72–74} ADCC function was also reported to be an important mechanism for achieving protective immunity for HIV-neutralizing antibodies.⁷⁵ Our synthetic and Fc γ receptor-binding studies of various pure Fc glycoforms demonstrate that addition of an appropriate bisecting sugar moiety at the *N*-glycan core could significantly enhance the affinity of Fc to the activating receptor (Fc γ RIIIa) while having little effects on affinity to the inhibitory receptor (Fc γ RIIb), pointing to a way to enhance the ADCC function of antibodies. It should be pointed out that previous structural and functional studies have suggested that the impact of Fc glycan structures on the affinity of Fc domain to Fc γ receptors are mainly due to their effects on the functional conformations of the Fc domain that are critical for the interactions between Fc domain and respective Fc γ receptors.^{9–15} Indeed, the Fc oligosaccharide can form multiple noncovalent interactions with the

protein surface of the C_H2 domain and, as shown in the crystal structures, a large portion of the glycans appears sandwiched between the two C_H2 domains. Nevertheless, it is still not clear how the addition of the bisecting GlcNAc or other (unnatural) bisecting sugar moiety precisely affects the local and/or global conformations of the Fc domain to favor its binding to Fc γ RIIIa. The synthetic, homogeneous Fc glycoforms obtained in the present work should be valuable for NMR and X-ray crystallographic structural studies for deciphering the precise molecular mechanism by which fine Fc *N*-glycans modulate the interaction between Fc domain and Fc γ receptors.

CONCLUSION

A convergent chemoenzymatic synthesis of an array of homogeneous IgG-Fc glycoforms was achieved through the Endo-A-catalyzed glycosylation remodeling approach. The results indicate that Endo-A is remarkably efficient to introduce various modified *N*-glycan core to Fc domain by transglycosylation with the *N*-glycan core oxazolines. However, either Endo-A or the Endo-M mutant (EndoM-N175A and EndoM-N175Q) was unable to efficiently transfer a full-length complex-type *N*-glycan to the Fc domain, implicating the limitations of Endo-A and Endo-M for IgG-Fc glycosylation remodeling. The availability of the synthetic homogeneous Fc glycoforms allowed a clear assessment on how the individual sugar residues within or flanking the pentasaccharide Man3GlcNAc2 core affect the binding of Fc to Fc γ receptors, Fc γ RIIIa and Fc γ RIIb. Specifically, our SPR binding studies provide unambiguous evidence that the presence of a bisecting sugar moiety at the *N*-glycan core, such as a GlcNAc or a mannose moiety, could directly enhance the affinity of Fc to Fc γ RIIIa receptor, independent of Fc fucosylation. In contrast, the presence of a bisecting sugar moiety shows no effect on the interaction between Fc and the inhibitory Fc γ receptor Fc γ RIIb. These results implicate a new way to enhance antibody's ADCC function by introducing an appropriate bisecting sugar moiety at the Fc glycan. To further expand the scope of this chemoenzymatic method for IgG-Fc glycosylation remodeling, we are currently performing site-directed mutagenesis of Endo-A and are also testing other endoglycosidases in order to find an enzyme or mutants capable of effectively transferring full-length complex-type *N*-glycans to IgG-Fc domain. We look forward to reporting new findings from these studies.

EXPERIMENTAL SECTION

Materials and Methods. Endo- β -*N*-acetylglucosaminidase from *Arthrobacter protophormiae* (Endo-A) was overproduced in *E. coli* following the reported procedure.⁷⁶ Bovine milk β -1,4-galactosyltransferase was purchased from Sigma-Aldrich (St. Louis, MO). PNGase F was purchased from New England Biolabs (Ipswich, MA). UDP-Gal was purchased from EMD Chemicals Inc. (Gibbstown, NJ). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO) without further purification. TLC was performed using Silica-gel on aluminum plates (Sigma-Aldrich). Flash column chromatography was performed on silica gel 60 (230–400 mesh). NMR spectra were recorded on JEOL ECX 400 MHz spectrometer. The chemical shifts were assigned in ppm. Analytical RP-HPLC was performed on a Waters 626 HPLC instrument with a Symmetry300TM C18 column (3.5 μm , 4.6 mm \times 250 mm) at 40 $^{\circ}\text{C}$. The column was

eluted with a linear gradient 0–90% MeCN containing 0.1% TFA for 20 min at the flow rate of 1.0 mL/min. MALDI-TOF/MS spectra were recorded on an Autoflex MALDI-TOF mass spectrometer (Bruker Daltonics, Billerica, MA) by using 2,5-dihydroxybenzoic acid as a matrix under positive ion conditions. High-resolution mass spectra (HRMS) were measured on a MALDI-TOF/TOF 4800 spectrometer (Applied Biosystems) with 2,5-dihydroxybenzoic acid as matrix and Cal 4700 standard peptide mixture (Applied Biosystems) was used as the internal standard.

Synthesis of Benzyl 2-O-Benzyl-4,6-O-benzylidene-3-O-p-methoxybenzyl- β -D-mannopyranosyl-(1 \rightarrow 4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido- β -D-glucopyranoside (9). A mixture of phenyl 2-O-benzyl-4,6-O-benzylidene-3-O-p-methoxybenzyl-1-thio- α -D-mannopyranoside **8**⁵⁷ (140 mg, 0.25 mmol), BSP (56.7 mg, 0.27 mmol), TTBP (122 mg, 0.49 mmol), and activated 3 Å molecular sieves (588 mg) in CH₂Cl₂ (4.9 mL) was stirred for 20 min at –60 °C under an argon atmosphere. Then Tf₂O (50 μ L, 0.30 mmol) was added, followed by the addition of a solution of benzyl 3,6-di-O-benzyl-2-deoxy-2-phthalimido- β -D-glucopyranoside **7** (111 mg 0.19 mmol) in CH₂Cl₂ (4.8 mL). The mixture was stirred at –60 °C for 1 h and then warmed to room temperature over a period of 1 h. The mixture was filtered through a Celite pad. The filtrate was diluted with CH₂Cl₂, washed sequentially with saturated NaHCO₃ and brine. The organic layer was dried over MgSO₄, filtered, and concentrated. The residue was subjected to silica gel column chromatography (hexanes/EtOAc, 7:2) to afford **9** (112 mg, 56%) as a white amorphous powder. ESI-MS: calcd for C₆₃H₆₁NO₁₃, *M* = 1039.41; Found (*m/z*), 1062.43 [*M* + Na]⁺; ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.77–6.79 (m, 33H), 5.51 (s, 1H), 5.11 (d, 1H, *J* = 8.3 Hz), 4.89–4.78 (m, 2H), 4.68–4.64 (m, 2H), 4.55–4.47 (m, 3H), 4.43–4.39 (m, 2H), 4.26–4.15 (m, 3H), 4.08–4.00 (m, 2H), 3.79 (s, 3H), 3.72 (m, 1H), 3.67 (dd, 1H, *J* = 11.3, 1.6 Hz), 3.59–3.53 (m, 2H), 3.47 (m, 1H), 3.41 (dd, 1H, *J* = 9.9, 3.0 Hz), 3.14 (dt, 1H, *J* = 9.6, 4.6 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 167.65, 159.08, 138.70, 138.59, 137.74, 137.61, 137.13, 133.53, 131.57, 130.54, 129.00, 128.75, 128.48, 128.23, 128.10, 127.90, 127.76, 127.70, 127.55, 127.51, 127.47, 126.82, 126.04, 123.11, 113.66, 101.92, 101.25, 97.32, 79.44, 78.60, 77.93, 76.95, 76.90, 74.90, 74.64, 74.55, 73.51, 72.21, 70.66, 68.50, 68.46, 67.27, 55.64, 55.20.

Synthesis of Benzyl 2-O-Benzyl-3-O-p-methoxybenzyl- β -D-mannopyranosyl-(1 \rightarrow 4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido- β -D-glucopyranoside (10). A solution of **9** (50 mg, 48 μ mol) in 80% aqueous solution of AcOH (5 mL) was stirred at 40 °C. After stirring for 6 h, the mixture was concentrated and purified by silica gel column chromatography (hexanes/EtOAc, 1:2) to afford **10** (36 mg, 80%) as a white amorphous powder. ESI-MS: calcd for C₅₆H₅₇NO₁₃, *M* = 951.38; Found (*m/z*), 973.52 [*M* + Na]⁺; ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.87–6.82 (m, 28H), 5.14 (d, 1H, *J* = 7.8 Hz), 4.89–4.71 (m, 5H), 4.55–4.49 (m, 3H), 4.43–4.37 (m, 2H), 4.29–4.20 (m, 3H), 4.02 (dd, 1H, *J* = 9.6, 8.2 Hz), 3.81–3.69 (m, 8H), 3.60 (m, 1H), 3.45 (m, 1H), 3.17 (m, 1H), 3.11 (dd, 1H, *J* = 9.6, 2.8 Hz), 2.18 (d, 1H, *J* = 1.8 Hz), 1.98 (t, 1H, *J* = 6.6 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 167.66, 159.37, 138.57, 138.42, 137.82, 137.14, 133.61, 131.56, 129.72, 129.25, 128.53, 128.20, 128.11, 127.84, 127.58, 127.53, 127.50, 127.41, 127.00, 123.17, 113.92, 101.10, 97.33, 81.63, 78.91, 76.80, 75.67, 74.71, 74.44, 74.29, 74.18, 73.62, 70.93, 70.67, 68.69, 67.15, 62.75, 55.63, 55.24.

Synthesis of Benzyl 2-O-Benzyl-6-O-tert-butylidimethylsilyl-3-O-p-methoxybenzyl- β -D-mannopyranosyl-(1 \rightarrow 4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido- β -D-glucopyranoside (11). To a solution of **10** (455 mg, 0.48 mmol) in pyridine (5 mL) was added tert-butylidimethylchlorosilane (144 mg, 0.96 mmol) at room temperature. After 2 h, the reaction solution was diluted with CH₂Cl₂, washed with saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated and the residue was purified by column chromatography on silica gel (hexanes/EtOAc, 3:1) to provide **11** (483 mg, 95%) as a white amorphous powder. ESI-MS: calcd for C₆₂H₇₁NO₁₃Si, *M* = 1066.31; Found (*m/z*), 1089.58 [*M* + Na]⁺; ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.87–6.74 (m, 28H), 5.11 (m, 1H), 4.87–4.75 (m, 4H), 4.67 (d, 1H, *J* = 11.9 Hz), 4.53–4.38 (m, 6H), 4.22–4.18 (m, 2H), 4.04–3.94 (m, 2H), 3.81 (dd, 1H, *J* = 10.1, 4.6 Hz), 3.78 (s, 3H), 3.74–3.67 (m, 2H), 3.65–3.59 (m, 2H), 3.51 (m, 1H), 3.36 (s, 1H), 3.22–3.13 (m, 2H), 0.84 (s, 9H), 0.02, –0.01 (2s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 167.67, 159.11, 138.89, 138.83, 137.86, 137.16, 133.48, 131.59, 130.45, 129.18, 128.46, 128.07, 128.05, 127.80, 127.75, 127.68, 127.60, 127.55, 127.49, 127.24, 126.67, 123.07, 113.73, 101.29, 97.32, 81.23, 78.98, 76.79, 75.07, 74.74, 74.32, 74.20, 74.11, 73.48, 71.53, 70.65, 68.57, 65.38, 55.65, 55.20, 25.74, 18.02, –5.65, –5.70.

Synthesis of Benzyl 3,4,6-Tri-O-acetyl-2-deoxy-2-phthalimido- β -D-glucopyranosyl-(1 \rightarrow 4)-2-O-benzyl-6-O-tert-butylidimethylsilyl-3-O-p-methoxybenzyl- β -D-mannopyranosyl-(1 \rightarrow 4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido- β -D-glucopyranoside (13). A solution of **11** (23 mg, 22 μ mol) and 2,3,4-tri-O-acetyl-2-deoxy-2-phthalimido- β -D-glucopyranosyl trichloroacetimidate **12**⁵⁸ (25 mg, 44 μ mol) in CH₂Cl₂ (1 mL) containing activated 4 Å molecular sieves (120 mg) was stirred under an atmosphere of argon at room temperature for 30 min. After cooling to –20 °C, a solution of BF₃·OEt₂ in CH₂Cl₂ (0.1 M, 87 μ L, 8.7 μ mol) was added, and the resulting mixture was stirred at room temperature overnight. Triethylamine (10 μ L) was then added, and the mixture was filtered through a Celite pad. The filtrate was sequentially washed with saturated NaHCO₃ and brine, dried over MgSO₄, filtered, and concentrated. The residue was subjected to flash silica gel column chromatography (hexanes/EtOAc, 5:2) to provide **13** (25 mg, 76%) as a white amorphous powder. ESI-MS: calcd for C₈₂H₉₀N₂O₂₂Si, *M* = 1482.57; Found (*m/z*), 1505.81 [*M* + Na]⁺; ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.86–6.59 (m, 32H), 5.76 (dd, 1H, *J* = 10.8, 9.0 Hz), 5.56 (d, 1H, *J* = 8.7 Hz), 5.11 (t, 1H, *J* = 9.6 Hz), 5.03 (m, 1H), 4.79–4.69 (m, 4H), 4.63–4.58 (m, 2H), 4.47–4.36 (m, 5H), 4.26 (dd, 1H, *J* = 10.8, 8.5 Hz), 4.15–4.06 (m, 4H), 3.95–3.89 (m, 2H), 3.82 (s, 3H), 3.69–3.55 (m, 5H), 3.46 (m, 1H), 3.27–3.21 (m, 2H), 2.97 (m, 1H), 1.99, 1.93, 1.84 (3s, 9H), 0.77 (s, 9H), –0.04, –0.14 (2s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.69, 170.04, 169.48, 167.52, 158.80, 138.96, 138.90, 137.84, 137.15, 134.35, 133.26, 131.60, 131.20, 130.97, 128.40, 128.15, 128.02, 127.92, 127.82, 127.72, 127.51, 127.47, 127.43, 127.04, 126.47, 123.62, 122.97, 113.66, 100.95, 97.23, 97.07, 79.86, 78.73, 76.86, 76.23, 75.68, 74.65, 74.26, 73.99, 73.49, 73.41, 71.32, 71.13, 70.69, 70.57, 68.92, 68.60, 61.84, 61.78, 55.58, 55.31, 55.22, 25.68, 20.60, 20.56, 20.39, 17.98, –5.41, –5.56.

Synthesis of Benzyl 3,4,6-Tri-O-acetyl-2-deoxy-2-phthalimido- β -D-glucopyranosyl-(1 \rightarrow 4)-2-O-benzyl- β -D-mannopyranosyl-(1 \rightarrow 4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido- β -D-glucopyranoside (14). To a stirred solution of compound **13** (302 mg, 0.20 mmol) in CH₂Cl₂ (20 mL) was added TFA

(3.75 mL) at 0 °C. The solution was stirred at 0 °C for 1 h, and MeOH (2 mL) was added. The mixture was sequentially washed with saturated NaHCO₃ and brine. The organic layer was then dried over MgSO₄ and filtered. The filtrate was concentrated by evaporation, and the residue was purified by column chromatography on silica gel (hexanes/EtOAc, 1:1) to yield **14** (224 mg, 88%) as a white solid. ESI-MS: calcd for C₆₈H₆₈N₂O₂₁, *M* = 1248.43; Found (*m/z*), 1271.58 [*M* + Na]⁺; ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.88–6.73 (m, 28H), 5.78 (dd, 1H, *J* = 10.6, 9.2 Hz), 5.42 (d, 1H, *J* = 8.7 Hz), 5.12 (t, 1H, *J* = 9.6 Hz), 5.05 (m, 1H), 4.86–4.65 (m, 5H), 4.47–4.41 (m, 3H), 4.36–4.30 (m, 2H), 4.27 (dd, 1H, *J* = 12.4, 2.3 Hz), 4.27 (dd, 1H, *J* = 12.4, 6.5 Hz), 4.16–4.12 (m, 2H), 3.98 (m, 1H), 3.89 (m, 1H), 3.85 (d, 1H, *J* = 2.8 Hz), 3.73 (t, 1H, *J* = 9.2 Hz), 3.67–3.63 (m, 2H), 3.56 (dd, 1H, *J* = 11.0, 3.3 Hz), 3.44–3.38 (m, 2H), 3.14 (m, 1H), 2.08, 2.04, 1.85 (3s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 170.58, 169.91, 169.44, 167.68, 138.70, 138.43, 137.56, 137.09, 134.47, 133.49, 131.50, 128.48, 128.05, 127.92, 127.71, 127.50, 127.46, 127.34, 127.28, 126.80, 123.64, 123.08, 100.66, 98.53, 97.23, 79.13, 78.62, 77.43, 76.69, 74.85, 74.54, 74.26, 74.06, 73.51, 72.96, 71.84, 70.59, 70.34, 68.81, 68.02, 61.94, 61.15, 55.54, 54.53, 20.55, 20.52, 20.32.

Synthesis of Benzyl 2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl-(1→3)-[3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→4)]-[2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1→6)]-2-O-benzyl-β-D-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (16). A solution of **14** (50 mg, 40 μmol) and 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl trichloroacetimidate **15**⁷⁷ (197 mg, 0.40 mmol) in CH₂Cl₂ (2.5 mL) containing activated 4 Å molecular sieves (296 mg) was stirred under an atmosphere of argon at room temperature for 30 min. After cooling to –20 °C, a solution of TMSOTf in CH₂Cl₂ (1 M, 80 μL, 80 μmol) was added and the resulting mixture was stirred at room temperature overnight. Triethylamine (10 μL) was then added, and the mixture was filtered through a Celite pad. The filtrate was sequentially washed with saturated NaHCO₃ and brine, dried over MgSO₄, and filtered. The filtrate was concentrated, and the residue was purified by silica gel column chromatography (hexanes/EtOAc, 2:3) to provide **16** (41 mg, 54%) as a white amorphous powder. ESI-MS: calcd for C₉₆H₁₀₄N₂O₃₉, *M* = 1909.84; Found (*m/z*): 1910.68 [*M* + H]⁺; ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.92–6.61 (m, 28H), 5.77 (dd, 1H, *J* = 10.5, 8.7 Hz), 5.64 (m, 1H), 5.45–5.39 (m, 2H), 5.34–5.20 (m, 4H), 5.11–5.04 (m, 3H), 4.93–4.81 (m, 3H), 4.77–4.73 (m, 2H), 4.64 (d, 1H, *J* = 12.8 Hz), 4.50–4.39 (m, 3H), 4.35–4.25 (m, 3H), 4.23–4.10 (m, 6H), 4.09–3.92 (m, 5H), 3.73 (m, 1H), 3.68–3.62 (m, 2H), 3.60–3.55 (m, 3H), 3.47 (m, 1H), 3.22 (dd, 1H, *J* = 9.6, 2.7 Hz), 2.32, 2.13, 2.10, 2.08, 2.06, 2.02, 2.01, 1.96, 1.92, 1.90, 1.86 (11s, 33H); ¹³C NMR (100 MHz, CDCl₃) δ 170.59, 170.56, 170.39, 170.30, 170.08, 169.60, 169.56, 169.39, 168.09, 167.50, 167.11, 138.11, 138.04, 137.67, 136.96, 134.96, 134.49, 133.51, 133.15, 131.53, 131.39, 131.08, 130.94, 128.37, 128.35, 128.23, 127.93, 127.73, 127.65, 127.52, 127.38, 127.31, 126.92, 123.61, 123.47, 123.18, 122.84, 99.58, 99.41, 97.20, 97.11, 96.88, 78.08, 77.12, 77.07, 75.85, 74.85, 74.59, 74.20, 74.05, 73.29, 72.31, 70.66, 70.46, 69.53, 69.48, 69.22, 68.98, 68.65, 68.40, 68.16, 67.86, 66.67, 65.62, 65.32, 62.67, 62.51, 62.44, 55.52, 54.16, 20.98, 20.93, 20.77, 20.66, 20.63, 20.56, 20.53, 20.50, 20.39, 20.32.

Synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl-(1→3)-[2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→4)]-[2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1→6)]-2-O-acetyl-β-D-mannopyranosyl-(1→4)-2-acetamido-1,3,6-tri-O-acetyl-2-deoxy-β-D-glucopyranose (18). Compound **16** (173 mg,

91 μmol) was dissolved in EtOH/H₂O/NH₂NH₂ monohydrate (10:1:1, 12 mL), and the mixture was stirred at 80 °C overnight. The mixture was concentrated in vacuo, and the residue was treated with Ac₂O/pyridine (1:1, 10 mL) at room temperature overnight. The mixture was concentrated, diluted with CH₂Cl₂, and washed sequentially with 1 M HCl, saturated NaHCO₃, and brine. The organic layer was dried over MgSO₄ and filtered. The filtrate was concentrated. Silica gel column chromatography (CH₂Cl₂/MeOH, 30:1) of the residue afforded compound **17** (122 mg, 77%) as a white powder. Without further purification, compound **17** thus obtained was dissolved in CH₂Cl₂–MeOH–AcOH (20:80:1, v/v, 12 mL), and 20% palladium(II) hydroxide on activated carbon (120 mg) was added. The mixture was vigorously stirred at room temperature under hydrogen atmosphere overnight and then filtered through a Celite pad. The filtrate was concentrated in vacuo. Pyridine (10 mL) and Ac₂O (10 mL) were added, and the mixture was stirred at room temperature overnight. The mixture was concentrated, diluted with CH₂Cl₂, washed sequentially with 1 M HCl, saturated NaHCO₃, and brine. The organic layer was dried over MgSO₄ and filtered. The filtrate was concentrated. Silica gel column chromatography (CH₂Cl₂/MeOH, 45:1) of the residue afforded **18** (97 mg, 89% from **17**) as a white amorphous powder. ESI-MS: calcd for C₆₄H₈₈N₂O₄₁, *M* = 1541.37; Found (*m/z*): 1563.75 [*M* + Na]⁺; ¹H NMR (400 MHz, CDCl₃, TMS, selected signals) δ 6.07 (d, 1H, *J* = 3.7 Hz), 5.96–5.88 (m, 2H), 4.69 (d, 1H, *J* = 8.7 Hz), 2.21–1.94 (m, 51H); ¹³C NMR (100 MHz, CDCl₃) δ 171.02, 170.88, 170.55, 170.40, 170.35, 170.27, 170.23, 170.00, 169.83, 169.68, 169.60, 169.49, 169.06, 168.98, 100.07, 97.39, 96.80, 90.46, 75.13, 73.60, 73.14, 72.39, 72.05, 71.86, 71.20, 69.78, 68.87, 68.74, 68.48, 68.40, 66.37, 65.72, 65.23, 62.56, 62.06, 61.75, 61.67, 54.06, 50.59, 22.85, 22.61, 20.73, 20.57, 20.45, 20.36, 20.29, 20.20.

Synthesis of 2-Methyl-[2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1→3)-[2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→4)]-[2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1→6)]-2-O-acetyl-β-D-mannopyranosyl-(1→4)-3,6-di-O-acetyl-1,2-dideoxy-α-D-glucopyranosyl-[2,1-d]-2-oxazoline (19). To a solution of **18** (55 mg, 36 μmol) in dichloroethane (3.5 mL) containing activated 4 Å molecular sieves (420 mg) were added 2,4,6-collidine (71 μL, 0.53 mmol), TMSBr (69 μL, 0.53 mmol), and BF₃·OEt₂ (67 μL, 0.53 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with CH₂Cl₂, filtered through a Celite pad, and washed sequentially with saturated NaHCO₃ and brine. The organic layer was dried over MgSO₄ and filtered. The filtrate was concentrated, and the residue was subjected to silica gel chromatography (CH₂Cl₂/MeOH, 50:1) on silica gel to give **19** (25 mg, 48%) as a white amorphous powder. ESI-MS: calcd for C₆₂H₈₄N₂O₃₉, *M* = 1480.47; Found (*m/z*): 1481.69 [*M* + H]⁺; ¹H NMR (400 MHz, CDCl₃, TMS) δ 6.00 (d, 1H, *J* = 9.1 Hz), 5.91 (d, 1H, *J* = 7.4 Hz), 5.54 (m, 1H), 5.36–5.04 (m, 10H), 5.01 (d, 1H, *J* = 1.4 Hz), 4.75 (s, 1H), 4.66 (d, 1H, *J* = 8.7 Hz), 4.39–3.76 (m, 17H), 3.59 (m, 1H), 3.50 (m, 1H), 3.43 (m, 1H), 2.21–1.94 (m, 48H); ¹³C NMR (100 MHz, CDCl₃) δ 171.14, 170.84, 170.64, 170.60, 170.55, 169.98, 169.86, 169.73, 169.60, 169.57, 169.55, 169.49, 169.25, 165.93, 100.36, 99.08, 99.03, 98.41, 97.71, 76.07, 74.48, 74.38, 72.65, 72.40, 72.11, 69.77, 69.60, 69.39, 68.97, 68.93, 68.84, 68.81, 68.59, 68.48, 67.78, 66.76, 65.98, 65.79, 64.60, 63.46, 63.18, 62.35, 62.22, 54.36, 23.03, 20.92, 20.82, 20.78, 20.71, 20.68, 20.64, 20.61, 20.56, 20.54, 20.47, 13.60.

Synthesis of 2-Methyl-[α-D-mannopyranosyl-(1→3)]-[2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→4)]-[α-D-mannopyranosyl-(1→6)]-β-D-mannopyranosyl-(1→4)-1,2-dideoxy-α-D-glucopyranosyl-[2,1-d]-2-oxazoline (1). To a solution of **19**

(23 mg, 16 μ mol) in MeOH (2 mL) was added MeONa in MeOH (0.5 M, 3.2 μ L, 1.6 μ mol). After stirring at room temperature overnight, the reaction mixture was concentrated to dryness. The residue was dissolved in water and lyophilized to give sugar oxazoline **1** (14 mg, quantitative). ESI-MS: calcd for $C_{34}H_{56}N_2O_{25}$, $M = 892.32$; Found (m/z), 893.78 [$M + H$]⁺; MALDI-TOF HRMS: calcd for [$M + Na$]⁺, 915.3070; found (m/z), 915.3048; ¹H NMR (400 MHz, D₂O) δ 5.96 (d, 1H, $J = 7.3$ Hz), 5.10 (s, 1H), 4.89 (s, 1H), 4.59 (m, 1H), 4.40 (d, 1H, $J = 8.2$ Hz), 4.24 (m, 1H), 4.09–3.23 (m, 29H), 1.94–1.92 (m, 6H); ¹³C NMR (100 MHz, D₂O) δ 174.61, 168.73, 101.83, 101.18, 101.06, 100.31, 99.93, 77.82, 77.24, 76.43, 74.26, 73.44, 73.15, 70.85, 70.48, 70.40, 70.23, 69.88, 69.84, 69.14, 66.91, 66.87, 65.70, 65.10, 61.70, 61.47, 61.13, 56.16, 22.19, 13.00.

Preparation of Free Bisecting GlcNAc-Containing Oligosaccharide 20. A solution of peracetylated pentasaccharide **18** (50 mg, 32.4 μ mol) in MeOH (2 mL) containing a catalytic amount of MeONa was stirred at room temperature overnight. The reaction mixture was neutralized with Dowex 50W-X8 (H⁺ form) and filtered. The filtrate was concentrated to dryness. The residue was dissolved in water and lyophilized to give free pentasaccharide **20** (30 mg, quantitative). ESI-MS: calcd for $C_{34}H_{58}N_2O_{26}$, $M = 910.33$, Found (m/z): 933.37 [$M + Na$]⁺; ¹H NMR (400 MHz, D₂O) δ 5.10 (s, 1H), 5.07 (m, 0.7H, α H-1 of GlcNAc-1), 4.82 (s, 1H), 4.63 (m, 1H), 4.40 (m, 1H), 4.16–3.23 (m, 30H), 1.93 (m, 6H); ¹³C NMR (100 MHz, D₂O) δ 174.61, 101.93, 101.18, 100.86, 100.11, 100.03, 94.92, 79.92, 77.34, 76.43, 74.56, 73.44, 73.15, 70.65, 70.48, 70.24, 70.03, 69.98, 69.84, 69.14, 66.91, 66.67, 65.80, 65.10, 61.40, 61.17, 60.03, 56.16, 22.19, 21.90.

Synthesis of Sugar Oxazoline 1 by the DMC-Based One-Pot Method. A solution of pentasaccharide **20** (15 mg, 16.5 μ mol), 2-chloro-1,3-dimethylimidazolinium chloride (DMC) (50 mg, 295 μ mol) and Et₃N (90 μ L, 648 μ mol) in water (400 μ L) was stirred at 4 °C for 1 h. The reaction mixture was subjected to gel filtration chromatography on a Sephadex G-10 column eluted by 0.05% aqueous Et₃N. The fractions containing the product were combined and lyophilized to give oxazoline **1** as a white powder (15 mg, quantitative yield). The sugar oxazoline obtained by this method was identical to the above synthesized compound as confirmed by ¹H NMR, ¹³C NMR, and ESI-MS.

Synthesis of Bisecting LacNAc-Containing Hexasaccharide 21. A solution of pentasaccharide **20** (15 mg, 16.5 μ mol) and UDP-Gal (15 mg, 24.9 μ mol) in a HEPES buffer (50 mM, pH 7.5, 1.5 mL) containing α -lactalbumin (0.2 mg/mL) and Mn²⁺ (20 mM) was incubated with β -1,4-galactosyltransferase (1 U) at 37 °C for 6 h. The reaction mixture was subject to gel filtration chromatography on a Sephadex G-10 column eluted by 0.05% aqueous Et₃N. The fractions containing the product were combined and lyophilized to give hexasaccharide **21** as a white solid (18 mg, quantitative yield). ESI-MS: calcd for $C_{40}H_{68}N_2O_{31}$, $M = 1072.38$, Found (m/z): 1095.03 [$M + Na$]⁺. ¹H NMR (400 MHz, D₂O) δ 5.10 (s, 1H), 5.08 (m, 0.65H, α H-1 of GlcNAc-1), 4.81 (s, 1H), 4.61 (m, 1H), 4.42 (d, 1H, $J = 6.8$ Hz), 4.32 (d, 1H, $J = 7.6$ Hz), 4.24–3.36 (m, 35H), 3.08 (m, 1H), 1.93 (m, 6H). ¹³C NMR (100 MHz, D₂O) δ 174.62, 101.95, 101.02, 100.89, 100.28, 100.14, 100.07, 94.92, 79.96, 77.38, 76.40, 74.59, 74.19, 73.86, 73.56, 73.42, 73.33, 73.10, 72.24, 70.50, 70.41, 70.27, 70.21, 70.02, 69.92, 69.88, 69.68, 69.12, 67.65, 66.90, 66.83, 65.78, 65.14, 61.47, 61.18, 60.06, 56.12, 53.56, 22.16, 21.95.

Synthesis of Bisecting LacNAc-Containing Sugar Oxazoline 2. A solution of hexasaccharide **21** (15 mg, 14.0 μ mol), 2-chloro-1,3-dimethylimidazolinium chloride (DMC) (50 mg, 295 μ mol) and Et₃N (90 μ L, 648 μ mol) in water (400 μ L) was stirred at 4 °C for 1 h. The reaction mixture was subjected to gel filtration chromatography on a Sephadex G-10 column eluted by 0.05% aqueous Et₃N. The fractions containing the product were combined and lyophilized to give oxazoline **2** (15 mg, quantitative yield) as a white powder. ESI-MS: calcd for $C_{40}H_{66}N_2O_{30}$, $M = 1054.37$, Found (m/z): 1055.42 [$M + H$]⁺. MALDI-TOF HRMS: calcd for [$M + Na$]⁺, 1077.3598; found (m/z), 1077.3638; ¹H NMR (400 MHz, D₂O) δ 5.97 (d, 1H, $J = 6.8$ Hz), 5.10 (s, 1H), 4.88 (d, 1H, $J = 1.6$ Hz), 4.59 (s, 1H), 4.43 (d, 1H, $J = 7.6$ Hz), 4.32 (d, 1H, $J = 8.0$ Hz), 4.24 (m, 1H), 1.94–1.92 (m, 6H). ¹³C NMR (100 MHz, D₂O, selected from ¹H–¹³C HMQC) δ 102.35, 101.85, 101.33, 100.46, 99.67, 99.56, 82.58, 79.23, 77.87, 76.02, 74.33, 74.18, 72.68, 72.17, 71.25, 70.97, 70.57, 70.12, 69.27, 68.87, 68.53, 67.32, 66.56, 65.65, 61.32, 56.02, 53.88, 22.56, 13.27.

Synthesis of Benzyl 2-O-Benzoyl-4,6-O-benzylidene-3-O-p-methoxybenzyl- β -D-glucopyranosyl-(1 \rightarrow 4)-2-azido-3,6-di-O-benzyl-2-deoxy- β -D-glucopyranoside (24). Ethyl 2-O-benzyl-4,6-O-benzylidene-3-O-p-methoxybenzyl-1-thio- β -D-glucopyranoside **22**⁶² (677 mg, 1.26 mmol), benzyl 2-azido-3,6-di-O-benzyl-2-deoxy- β -D-glucopyranoside **23** (500 mg, 1.05 mmol) and 4 Å molecular sieves (1.44 g) were stirred in dichloroethane (12 mL) at room temperature for 30 min and the mixture was then cooled to 0 °C. A solution of NIS (290 mg, 1.29 mmol) and TfOH (12.6 μ L, 142 μ mol) in CH₂Cl₂–Et₂O (1:1, 12.6 mL) was added to the mixture, and the resulting mixture was stirred for 30 min at 0 °C. Et₃N (60 μ L) was added, and the reaction mixture was filtered through a Celite pad. The filtrate was diluted with CH₂Cl₂, and washed sequentially with 10% Na₂S₂O₃, saturated NaHCO₃, and brine. The organic layer was dried over MgSO₄, filtered, and concentrated. The residue was subjected to silica gel column chromatography (hexanes/EtOAc, 6:1) to give **24** (632 mg, 63%) as a white amorphous powder. ESI-MS: calcd for $C_{55}H_{55}N_3O_{12}$, $M = 949.3786$; Found (m/z): 950.51 [$M + H$]⁺. ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.86–6.58 (m, 29H), 5.52 (s, 1H), 5.19 (t, 1H, $J = 8.5$ Hz), 4.93 (d, 1H, $J = 10.6$ Hz), 4.84 (d, 1H, $J = 11.9$ Hz), 4.73 (d, 1H, $J = 10.5$ Hz), 4.72 (d, 1H, $J = 11.5$ Hz), 4.68 (d, 1H, $J = 7.8$ Hz), 4.66 (d, 1H, $J = 12.4$ Hz), 4.58 (d, 1H, $J = 11.9$ Hz), 4.57 (d, 1H, $J = 11.9$ Hz), 4.30 (d, 1H, $J = 12.4$ Hz), 4.20–4.16 (m, 2H), 3.99 (t, 1H, $J = 9.4$ Hz), 3.75–3.63 (m, 5H), 3.59 (dd, 1H, $J = 11.3$, 3.0 Hz), 3.49–3.41 (m, 3H), 3.33–3.22 (m, 2H), 3.08 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 164.70, 159.06, 138.34, 137.91, 137.23, 136.72, 133.24, 129.89, 129.79, 129.63, 129.43, 129.03, 128.52, 128.37, 128.26, 128.21, 128.03, 127.97, 127.85, 127.81, 127.60, 126.01, 113.51, 101.21, 100.66, 100.31, 81.85, 81.11, 77.21, 76.13, 75.30, 74.50, 73.78, 73.54, 73.46, 70.80, 68.50, 67.29, 66.04, 65.71, 55.07.

Synthesis of Benzyl 2-O-Benzoyl-4,6-O-benzylidene- β -D-glucopyranosyl-(1 \rightarrow 4)-2-azido-3,6-di-O-benzyl-2-deoxy- β -D-glucopyranoside (25). To a solution of **24** (47 mg, 50 μ mol) in CH₂Cl₂–H₂O (17.5/1, 2.1 mL) was added DDQ (26 mg, 115 μ mol) at 0 °C. After 30 min, the reaction mixture was warmed to room temperature and further stirred for 2 h. The reaction mixture was diluted with CH₂Cl₂, washed with saturated NaHCO₃ and brine, and dried over MgSO₄. The mixture was filtered, and the filtrate was concentrated. The residue was subjected to silica gel column chromatography (hexanes/EtOAc, 4:1) to

provide **25** (36 mg, 87%) as a white amorphous powder. ESI-MS: calcd for $C_{47}H_{47}N_3O_{11}$, $M = 829.3211$; Found (m/z): 830.58 $[M + H]^+$. 1H NMR (400 MHz, $CDCl_3$, TMS) δ 7.99–7.26 (m, 25H), 5.48 (s, 1H), 5.16 (t, 1H, $J = 8.7$ Hz), 4.93 (d, 1H, $J = 10.5$ Hz), 4.86 (d, 1H, $J = 12.4$ Hz), 4.79 (d, 1H, $J = 8.3$ Hz), 4.75 (d, 1H, $J = 11.5$ Hz), 4.71 (d, 1H, $J = 12.4$ Hz), 4.59 (d, 1H, $J = 11.9$ Hz), 4.21–4.17 (m, 2H), 4.03 (t, 1H, $J = 9.2$ Hz), 3.89–3.83 (m, 1H), 3.69 (dd, 1H, $J = 11.0, 3.2$ Hz), 3.58–3.43 (m, 4H), 3.35–3.25 (m, 2H), 3.14 (m, 1H), 2.51 (d, 1H, $J = 3.2$ Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ 165.35, 138.33, 137.93, 136.81, 136.70, 133.44, 129.80, 129.34, 129.24, 128.53, 128.50, 128.37, 128.34, 128.21, 128.03, 127.91, 127.87, 127.81, 127.78, 127.62, 126.25, 101.86, 100.45, 100.32, 81.12, 80.87, 76.24, 75.26, 74.78, 74.52, 73.53, 72.29, 70.81, 68.40, 67.41, 66.01, 65.73.

Synthesis of Benzyl 2-O-Benzoyl-4-O-benzyl- β -D-glucopyranosyl-(1 \rightarrow 4)-2-azido-3,6-di-O-benzyl-2-deoxy- β -D-glucopyranoside (26**).** To a suspension of **25** (50 mg, 60 μ mol) and 4 Å molecular sieves (192 mg) in CH_2Cl_2 (1.6 mL) were added successively Et_3SiH (29 μ L, 181 μ mol) and $PhBCl_2$ (27 μ L, 205 μ mol) at $-78^\circ C$. After stirring at $-78^\circ C$ for 1 h, Et_3N (116 μ L) and MeOH (116 μ L) were added. The reaction mixture was diluted with CH_2Cl_2 , filtered through a Celite pad, and washed sequentially with saturated $NaHCO_3$ and brine. The organic layer was dried over $MgSO_4$, filtered, and concentrated. The resulting residue was subjected to silica gel column chromatography (hexanes/ $EtOAc$, 3:1) to afford **26** (47 mg, 94%) as a white amorphous powder. ESI-MS: calcd for $C_{47}H_{49}N_3O_{11}$, $M = 831.3367$; Found (m/z), 832.50 $[M + H]^+$. 1H NMR (400 MHz, $CDCl_3$, TMS) δ 7.95–7.26 (m, 25H), 5.02 (dd, 1H, $J = 9.2, 8.3$ Hz), 4.95 (d, 1H, $J = 11.0$ Hz), 4.86 (d, 1H, $J = 12.4$ Hz), 4.79–4.67 (m, 5H), 4.60 (d, 1H, $J = 11.9$ Hz), 4.41 (d, 1H, $J = 11.9$ Hz), 4.20 (d, 1H, $J = 7.8$ Hz), 3.97 (t, 1H, $J = 9.3$ Hz), 3.75 (dt, 1H, $J = 9.2, 3.7$ Hz), 3.70–3.65 (m, 2H), 3.53 (dd, 1H, $J = 11.0, 1.4$ Hz), 3.49–3.43 (m, 2H), 3.41–3.29 (m, 2H), 3.21 (ddd, 1H, $J = 9.5, 4.5, 2.6$ Hz), 3.15 (m, 1H), 2.31 (d, 1H, $J = 4.1$ Hz), 1.40 (t, 1H, $J = 7.1$ Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ 165.65, 138.36, 137.88, 137.79, 136.69, 133.38, 129.71, 129.25, 128.53, 128.51, 128.45, 128.39, 128.34, 127.99, 127.96, 127.85, 127.78, 127.69, 127.10, 100.26, 99.88, 81.06, 77.97, 76.13, 75.51, 75.13, 75.02, 74.70, 74.65, 74.48, 73.54, 70.75, 67.33, 65.79, 61.54.

Synthesis of Benzyl 6-O-Acetyl-2,3,4-tri-O-benzoyl- α -D-mannopyranosyl-(1 \rightarrow 3)-[6-O-acetyl-2,3,4-tri-O-benzoyl- α -D-mannopyranosyl-(1 \rightarrow 6)]-2-O-benzoyl-4-O-benzyl- β -D-glucopyranosyl-(1 \rightarrow 4)-2-azido-3,6-di-O-benzyl-2-deoxy- β -D-glucopyranoside (28**).** A solution of compound **26** (75 mg, 90 μ mol) and 2,3,4-tri-O-acetyl-6-O-benzoyl- α -D-mannopyranosyl trichloroacetimidate **27**⁷⁸ (305 mg, 449 μ mol) in CH_2Cl_2 (3.4 mL) containing activated 4 Å molecular sieves (456 mg) was stirred under an atmosphere of argon at room temperature for 30 min. After this mixture cooled to $-40^\circ C$, a solution of TMSOTf in CH_2Cl_2 (0.1 M, 450 μ L, 45 μ mol) was added and the resulting mixture was stirred at room temperature overnight. The mixture was filtered through a Celite pad. The filtrate was poured into saturated $NaHCO_3$, and extracted with CH_2Cl_2 . The organic layer was washed with brine, dried over $MgSO_4$, and filtered. The filtrate was concentrated, and the residue was subjected to silica gel column chromatography (hexanes/ $EtOAc$, 5:2) to provide **28** (159 mg, 95%) as a white amorphous. ESI-MS: calcd for $C_{105}H_{97}N_3O_{29}$; $M = 1864.90$; Found (m/z): 1865.83 $[M + H]^+$. 1H NMR (400 MHz, $CDCl_3$, TMS) δ 8.10–7.16 (m, 55H), 5.95–5.83 (m, 3H), 5.77–5.74 (m, 2H), 5.61 (t, 1H, $J = 2.0$ Hz),

5.51 (s, 1H), 5.37 (t, 1H, $J = 8.7$ Hz), 5.13 (d, 1H, $J = 0.9$ Hz), 5.07 (d, 1H, $J = 11.0$ Hz), 4.90 (d, 1H, $J = 11.5$ Hz), 4.84–4.80 (m, 2H), 4.76–4.69 (m, 3H), 4.54 (d, 1H, $J = 11.9$ Hz), 4.36 (d, 1H, $J = 11.9$ Hz), 4.28–4.02 (m, 7H), 3.89 (dd, 1H, $J = 12.1, 2.6$ Hz), 3.81 (d, 1H, $J = 11.0$ Hz), 3.73–3.61 (m, 3H), 3.54–3.43 (m, 4H), 3.28 (t, 1H, $J = 9.4$ Hz), 3.11 (d, 1H, $J = 9.6$ Hz), 2.08 (s, 3H), 1.99 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 170.61, 170.32, 165.44, 165.32, 165.26, 165.12, 165.04, 165.01, 164.65, 138.33, 137.90, 137.06, 136.82, 133.56, 133.49, 133.44, 133.43, 133.35, 133.27, 133.23, 133.07, 132.94, 130.05, 129.80, 129.76, 129.67, 129.59, 129.33, 129.23, 129.07, 128.98, 128.94, 128.80, 128.61, 128.56, 128.42, 128.34, 128.28, 128.23, 128.20, 128.15, 128.11, 128.07, 127.93, 127.88, 127.76, 127.71, 127.51, 100.60, 99.71, 98.60, 98.03, 80.77, 80.17, 79.28, 75.64, 75.26, 75.01, 74.70, 74.39, 73.63, 73.02, 70.76, 70.26, 69.95, 69.85, 69.70, 69.12, 68.91, 67.63, 67.49, 66.40, 65.87, 65.40, 62.30, 61.70, 20.66, 20.53.

Synthesis of Benzyl 6-O-Acetyl-2,3,4-tri-O-benzoyl- α -D-mannopyranosyl-(1 \rightarrow 3)-[6-O-acetyl-2,3,4-tri-O-benzoyl- α -D-mannopyranosyl-(1 \rightarrow 6)]-2-O-benzoyl-4-O-benzyl- β -D-glucopyranosyl-(1 \rightarrow 4)-2-acetamido-3,6-di-O-benzyl-2-deoxy- β -D-glucopyranoside (29**).** To a solution of **28** (604 mg, 0.324 mmol) in $CHCl_3$ (6 mL) was added pyridine (6 mL) and thioacetic acid ($AcSH$) (6 mL) at room temperature. After stirring for 48 h, the mixture was concentrated and the residue was subjected to silica gel column chromatography (hexanes/ $EtOAc$, 1:1) to afford **29** (474 mg, 78%). ESI-MS: calcd for $C_{107}H_{101}NO_{30}$; $M = 1880.94$; Found (m/z), 1881.68 $[M + H]^+$. 1H NMR (400 MHz, $CDCl_3$, TMS) δ 8.12–7.12 (m, 55H), 6.01–5.86 (m, 3H), 5.79–5.74 (m, 3H), 5.63 (d, 1H, $J = 8.7$ Hz), 5.54 (s, 1H), 5.43 (t, 1H, $J = 8.9$ Hz), 5.26 (s, 1H), 5.15 (d, 1H, $J = 11.5$ Hz), 4.83 (d, 1H, $J = 11.5$ Hz), 4.70 (d, 1H, $J = 8.2$ Hz), 4.65–4.53 (m, 5H), 4.35 (d, 1H, $J = 12.4$ Hz), 4.29 (dd, 1H, $J = 12.2, 4.4$ Hz), 4.24–4.07 (m, 6H), 3.96–3.83 (m, 4H), 3.77–3.69 (m, 3H), 3.64–3.62 (m, 2H), 3.51–3.46 (m, 2H), 2.09 (s, 3H), 1.99 (s, 3H), 1.81 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 170.65, 170.33, 170.04, 165.49, 165.46, 165.31, 165.24, 165.14, 165.05, 164.89, 138.44, 138.10, 137.66, 137.32, 133.54, 133.44, 133.33, 133.25, 133.10, 133.06, 129.82, 129.77, 129.65, 129.43, 129.30, 129.25, 129.00, 128.91, 128.76, 128.68, 128.61, 128.42, 128.25, 128.22, 128.06, 128.03, 127.95, 127.89, 127.73, 127.37, 127.31, 99.84, 99.05, 98.52, 98.10, 80.44, 78.77, 77.17, 75.35, 74.75, 74.36, 73.45, 72.80, 70.55, 70.25, 70.04, 69.87, 69.73, 69.01, 68.91, 66.80, 66.63, 65.86, 62.50, 61.77, 53.33, 23.25, 20.66, 20.53.

Synthesis of 2,3,4,6-Tetra-O-acetyl- α -D-mannopyranosyl-(1 \rightarrow 3)-[2,3,4,6-tetra-O-acetyl- α -D-mannopyranosyl-(1 \rightarrow 6)]-2,4-di-O-acetyl- β -D-glucopyranosyl-(1 \rightarrow 4)-2-acetamido-1,3,6-tri-O-acetyl-2-deoxy- β -D-glucopyranose (30**).** To a solution of **29** (95 mg, 54 μ mol) in MeOH/ CH_2Cl_2 (5:1, 10 mL) was added a solution of MeONa in MeOH (0.5 M, 400 μ L). The resulting mixture was stirred at room temperature overnight and then neutralized with Dowex 50W-X8 (H^+ form). The mixture was filtered, and the filtrate was concentrated. The residue was dissolved in MeOH (5 mL), and palladium(II) hydroxide (20%) on activated carbon (40 mg) was added. The resulting mixture was vigorously stirred at room temperature under hydrogen atmosphere for 24 h. The reaction mixture was filtered through a Celite pad, and the filtrate was concentrated in vacuo to dryness. The residue was dissolved in pyridine (3 mL) and Ac_2O (3 mL) for acetylation. The mixture was stirred at room temperature for 18 h and then concentrated in vacuo to dryness. The residue was subjected to silica gel column chromatography

(CH₂Cl₂/MeOH, 60:1 to 40:1) to give **30** (62 mg, 92% in three steps) as a white solid. ESI-MS: calcd for C₅₂H₇₁NO₃₄; $M = 1253.3858$; found (m/z): 1254.68 [$M + H^+$]. ¹H NMR (400 MHz, CDCl₃, TMS) δ 5.92 (d, 1H, $J = 7.3$ Hz), 5.78 (d, 1H, $J = 2.7$ Hz), 5.36–5.21 (m, 4H), 5.14–5.08 (m, 2H), 5.03–4.93 (m, 2H), 4.89 (d, 1H, $J = 1.8$ Hz), 4.79 (s, 1H), 4.70 (d, 1H, $J = 7.8$ Hz), 4.39 (dd, 1H, $J = 12.3, 4.5$ Hz), 4.24–4.18 (m, 2H), 4.16–3.99 (m, 5H), 3.95 (dt, 1H, $J = 10.1, 2.8$ Hz), 3.89–3.74 (m, 3H), 3.57 (m, 1H), 3.49–3.42 (m, 2H), 2.16–2.13 (m, 9H), 2.11–2.07 (m, 18H), 2.01 (s, 3H), 1.95–1.94 (m, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 170.68, 170.52, 170.49, 170.00, 169.96, 169.87, 169.54, 169.48, 169.33, 169.23, 166.21, 101.56, 99.67, 98.83, 97.46, 81.70, 78.24, 72.53, 71.98, 70.02, 69.52, 69.31, 69.19, 68.92, 68.82, 68.73, 68.40, 67.29, 65.68, 64.99, 64.36, 63.65, 61.97, 61.49, 20.89, 20.85, 20.78, 20.77, 20.68, 20.62, 20.56, 20.47, 20.44, 13.78.

Synthesis of 2-Methyl- $[\alpha$ -D-mannopyranosyl-(1 \rightarrow 3)]- $[\alpha$ -D-mannopyranosyl-(1 \rightarrow 6)]- $[\beta$ -D-glucopyranosyl-(1 \rightarrow 4)]-1,2-dideoxy- α -D-glucopyranol- $[\alpha$ -D-glucopyranosyl-(1 \rightarrow 4)]-2-oxazoline (4**).** To a solution of **30** (58 mg, 46 μ mol) in MeOH (2 mL) was added a catalytic amount of MeONa and the solution was stirred at room temperature overnight. The reaction mixture was neutralized with Dowex 50W-X8 (H⁺ form) and filtered. The filtrate was concentrated to dryness, and the residue was dissolved in water and lyophilized to give the free tetrasaccharide (33 mg, quantitative) (ESI-MS, found (m/z), 730.31 [$M + Na$]⁺). The free oligosaccharide was then dissolved in water (1 mL), and 2-chloro-1,3-dimethylimidazolinium chloride (DMC) (78 mg, 460 μ mol) and Et₃N (128 μ L, 920 μ mol) were added. The solution was stirred at 4 °C for 1 h. Then the reaction mixture was subjected to gel filtration on a Sephadex G-10 column eluted with 0.05% aqueous Et₃N. The fractions containing the product were combined and lyophilized to give oxazoline **4** (30 mg, 95%) as a white powder. ESI-MS: calcd for C₂₆H₄₃NO₂₀; $M = 689.24$; Found (m/z): 690.35 [$M + H$]⁺. MALDI-TOF HRMS: calcd for [$M + Na$]⁺, 712.2276; found (m/z), 712.2258; ¹H NMR (400 MHz, D₂O) δ 5.97 (d, 1H, $J = 7.3$ Hz), 5.08 (s, 1H), 4.79 (s, 1H), 4.40 (d, 1H, $J = 7.8$ Hz), 4.27 (m, 1H), 4.08 (m, 1H), 3.92 (m, 1H), 3.94–3.46 (m, 19H), 3.31 (m, 1H), 3.21 (m, 1H), 1.94 (s, 3H); ¹³C NMR (100 MHz, D₂O) δ 168.12, 104.60, 101.10, 99.93, 99.70, 82.25, 79.62, 74.07, 72.90, 72.76, 71.91, 71.02, 70.79, 70.66, 70.40, 69.96, 68.92, 66.91, 66.63, 65.60, 65.43, 61.93, 61.03, 60.67, 12.97.

Overproduction of Human IgG1-Fc in Chinese Hamster Ovary (CHO) Cell Lines. The expression of human IgG1-Fc in *Pichia pastoris* was performed following the procedure that we have previously described.³⁶ For producing recombinant IgG1-Fc in Chinese Hamster Ovary (CHO) cell lines, the CHO cells were transiently transfected with a mammalian expression plasmid pcDNA-Fc encoding the human Fc gene, using Fugene6 transfection reagent (Roche). After transfection, kifunensine was added into the medium to a final concentration of 2 μ g/mL. The expression of fusion protein was periodically monitored using an antihuman IgG1 Fc ELISA assay kit (Human IgG ELISA Quantitation Kit, BETHYL Laboratories Inc., Montgomery TX). The culture supernatant was collected 4 days after transfection. The Fc protein was purified by affinity chromatography using a protein A-agarose resin (Pierce). The cell-free culture supernatant was loaded on the protein A column that was pre-equilibrated with IgG binding buffer (pH 8.0, Thermo Scientific, Rockford, IL). After extensive wash with the same buffer, Fc protein was eluted with IgG elution buffer (pH 3.0, Thermo

Scientific, Rockford, IL). Each elution fraction was immediately neutralized with 1 M Tris, pH 8.8. Subsequently, the elution fractions were combined and concentrated by centrifugal filtration (Amicon Ultra centrifugal filter, Millipore, Billerica, MA). The integrity and purity of the recombinant IgG-Fc that carries high-mannose type N-glycans (HM-Fc) was checked by SDS-PAGE. MALDI-TOF MS of HM-Fc, calcd $M = 65444$ Da; found (m/z), 65447. MALDI-TOF MS of the PNGase F released N-glycan, calcd for Man₉GlcNAc₂, $M = 1883.67$ Da; found (m/z) 1906.40 [$M + Na$]⁺. For the production of the natural complex-type glycoform of IgG-Fc, the transfected CHO cells were grown in the absence of the α -mannosidase inhibitor kifunensine, and the recombinant IgG-Fc was purified following the same procedure.

Preparation of GlcNAc-Fc Homodimer. The recombinant IgG-Fc (HM-Fc) (15 mg) was treated with Endo-H (0.8 unit) in a phosphate buffer (3 mL, 50 mM, pH 6.5) at 30 °C. After 10 h, SDS-PAGE indicated the completion of the deglycosylation. The GlcNAc-Fc homodimer was then purified by protein A affinity chromatography. MALDI-TOF MS of GlcNAc-Fc: calcd $M = 62119$ Da; found (m/z), 62112.

Synthesis of the Bisecting-GlcNAc Fc Glycoform (Fc-1) by the Endo-A-Catalyzed Transglycosylation of GlcNAc-Fc. A solution of GlcNAc-Fc homodimer (1.20 mg, 19.3 nmol) and bi-GlcNAc-Man₃GlcNAc oxazoline **1** (0.345 mg, 386 nmol, about 10 equivalent for each of the GlcNAc moiety in the GlcNAc-Fc homodimer) in a phosphate buffer (50 mM, pH 7.0, 200 μ L) was incubated with Endo-A (8 μ g) at 23 °C. The enzymatic reactions were monitored by SDS-PAGE analysis and MALDI-TOF MS analysis of an aliquot of the reaction mixture. When all the GlcNAc-Fc was converted (after 3 h), the reaction mixture was subject to affinity chromatography on a protein A-agarose column, following the procedure described above for purification of the recombinant IgG1-Fc. The fractions containing the IgG-Fc glycoform were combined, desalted by ultracentrifugation, and lyophilized to give Fc-1 (1.1 mg) (quantified using the antihuman IgG1 Fc ELISA quantification kit). The purified IgG-Fc glycoform (Fc-1) was analyzed by MALDI-TOF MS. The homogeneity of the product was confirmed by SDS-PAGE analysis under reducing conditions. The attached N-glycan was released by PNGase F treatment and analyzed by MALDI-TOF MS following the previously reported procedure.³⁶ MALDI-TOF MS of Fc-1, calcd $M = 63905$ Da; found (m/z), 63909. PNGase F released N-glycan (bisecting-GlcNAc-Man₃GlcNAc₂): calcd for C₄₂H₇₁N₃O₃₁, $M = 1113.41$ Da; found (m/z), 1136.80 [$M + Na$]⁺.

Synthesis of Other Fc Glycoforms (Fc-2 to Fc-6) by the Endo-A-Catalyzed Transglycosylation of GlcNAc-Fc. The synthesis of glycoforms Fc-2, Fc-3, Fc-4, Fc-5, and Fc-6 was performed in the same way as described for the preparation of Fc-1, using excess of the corresponding sugar oxazoline (10–15 mol equiv of each of the GlcNAc moiety in the GlcNAc-Fc homodimer). After SDS-PAGE indicated the completion of the GlcNAc-Fc transformation, the product was purified on a protein A affinity column. The purity of the product was confirmed by SDS-PAGE analysis, and the identity was characterized by MALDI-TOF MS analysis of the intact Fc glycoforms and the released N-glycans.

Fc-2: calcd $M = 64229$ Da; found (m/z), 64212; the attached N-glycan (bisecting-LacNAc-Man₃GlcNAc₂): calcd for C₄₈H₈₁N₃O₃₆, $M = 1275.46$ Da; found (m/z), 1298.40 [$M + Na$]⁺.

Fc-3: calcd $M = 63822$ Da; found (m/z), 63840; the attached N -glycan (bisecting-Man-Man3GlcNAc2): calcd for $C_{40}H_{68}N_{2}O_{31}$, $M = 1072.38$ Da; found (m/z), 1095.10 $[M + Na]^+$.

Fc-4: calcd $M = 63498$ Da; found (m/z), 63506; the attached N -glycan (Man2GlcGlcNAc2): calcd for $C_{34}H_{58}N_{2}O_{26}$, $M = 910.33$ Da; found (m/z), 933.42 $[M + Na]^+$.

Fc-5: calcd $M = 63498$ Da; found (m/z), 63534; the attached N -glycan (Man3GlcNAc2): calcd for $C_{34}H_{58}N_{2}O_{26}$, $M = 910.33$ Da; found (m/z), 933.80 $[M + Na]^+$.

Fc-6: calcd $M = 62849$ Da; found (m/z), 62870; the attached N -glycan (ManGlcNAc2): calcd for $C_{22}H_{38}N_{2}O_{16}$, $M = 586.22$ Da; found (m/z), 609.70 $[M + Na]^+$.

SPR Studies. The binding between different glycoforms of IgG1-Fc and Fc γ IIIa receptor was measured by surface plasmon resonance (SPR) using a Biacore T100 instrument (GE Healthcare, U.S.A.). Protein A was immobilized on a CM5 biosensor chip (GE Healthcare, U.S.A.) at 2700 RU using a standard primary amine coupling chemistry at pH 4.5. A reference flow cell was prepared similarly without injecting protein A. To capture the different glycoforms of IgG1-Fc, each of the individual IgG1-Fc glycoforms in HBS-P buffer (10 mM HEPES, 150 mM NaCl, 0.05% surfactant P20, pH 7.4) was injected at 10 μ L/min onto the protein A surface until it reached the capture level of 100 RU. A series of dilutions of Fc γ IIIa receptor were injected at 10 μ L/min. After each cycle, the surface was regenerated by injecting 20 mM HCl at 10 μ L/min for 30 s. Data were fitted into a 1:1 steady-state binding model using Biacore T100 evaluation software, and the equilibrium constant K_D was derived.

■ ASSOCIATED CONTENT

Supporting Information. Complete author list of ref 32; amino acid sequence of the recombinant IgG1-Fc; reaction scheme and SDS-PAGE analysis for the transglycosylation of GlcNAc-Fc with complex-type N -glycan oxazoline. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

lwang@som.umaryland.edu

■ ACKNOWLEDGMENT

We thank Prof. Kaoru Takegawa (Kyushu University) for providing the pGEX-2T/Endo-A plasmid that was used for expressing the recombinant Endo-A, and the Gliknik Inc. for providing the mammalian expression vector pcDNA-Fc that was used for expressing the high-mannose type glycoform. This work was supported by the National Institutes of Health (NIH Grants R01 GM096973 and R01 GM080374).

■ REFERENCES

- (1) Adams, G. P.; Weiner, L. M. *Nat. Biotechnol.* **2005**, *23*, 1147–1157.
- (2) Jefferis, R. *Nat. Rev. Drug Discovery* **2009**, *8*, 226–234.
- (3) Aggarwal, S. *Nat. Biotechnol.* **2010**, *28*, 1165–1171.
- (4) Nimmerjahn, F.; Ravetch, J. V. *Nat. Rev. Immunol.* **2008**, *8*, 34–47.
- (5) Takahashi, N.; Nakagawa, H.; Fujikawa, K.; Kawamura, Y.; Tomiya, N. *Anal. Biochem.* **1995**, *226*, 139–146.
- (6) Wormald, M. R.; Rudd, P. M.; Harvey, D. J.; Chang, S. C.; Scragg, I. G.; Dwek, R. A. *Biochemistry* **1997**, *36*, 1370–1380.

- (7) Jefferis, R. *Biotechnol. Prog.* **2005**, *21*, 11–16.
- (8) Arnold, J. N.; Wormald, M. R.; Sim, R. B.; Rudd, P. M.; Dwek, R. A. *Annu. Rev. Immunol.* **2007**, *25*, 21–50.
- (9) Krapp, S.; Mimura, Y.; Jefferis, R.; Huber, R.; Sonderrmann, P. *J. Mol. Biol.* **2003**, *325*, 979–989.
- (10) Sonderrmann, P.; Huber, R.; Oosthuizen, V.; Jacob, U. *Nature* **2000**, *406*, 267–273.
- (11) Crispin, M.; Bowden, T. A.; Coles, C. H.; Harlos, K.; Aricescu, A. R.; Harvey, D. J.; Stuart, D. I.; Jones, E. Y. *J. Mol. Biol.* **2009**, *387*, 1061–1066.
- (12) Ferrara, C.; Grau, S.; Jager, C.; Sonderrmann, P.; Brunker, P.; Waldhauer, I.; Hennig, M.; Ruf, A.; Rufer, A. C.; Stihle, M.; Umana, P.; Benz, J. *Proc. Natl. Acad. Sci. U.S.A.* **2011**, *108*, 12669–12674.
- (13) Yamaguchi, Y.; Nishimura, M.; Nagano, M.; Yagi, H.; Sasakawa, H.; Uchida, K.; Shitara, K.; Kato, K. *Biochim. Biophys. Acta* **2006**, *1760*, 693–700.
- (14) Matsumiya, S.; Yamaguchi, Y.; Saito, J.; Nagano, M.; Sasakawa, H.; Otaki, S.; Satoh, M.; Shitara, K.; Kato, K. *J. Mol. Biol.* **2007**, *368*, 767–779.
- (15) Barb, A. W.; Prestegard, J. H. *Nat. Chem. Biol.* **2011**, *7*, 147–153.
- (16) Homans, S. W.; Dwek, R. A.; Fernandes, D. L.; Rademacher, T. W. *Biochim. Biophys. Acta* **1984**, *798*, 78–83.
- (17) Nimmerjahn, F.; Ravetch, J. V. *Annu. Rev. Immunol.* **2008**, *26*, 513–533.
- (18) Shields, R. L.; Lai, J.; Keck, R.; O'Connell, L. Y.; Hong, K.; Meng, Y. G.; Weikert, S. H.; Presta, L. G. *J. Biol. Chem.* **2002**, *277*, 26733–26740.
- (19) Shinkawa, T.; Nakamura, K.; Yamane, N.; Shoji-Hosaka, E.; Kanda, Y.; Sakurada, M.; Uchida, K.; Anazawa, H.; Satoh, M.; Yamasaki, M.; Hanai, N.; Shitara, K. *J. Biol. Chem.* **2003**, *278*, 3466–3473.
- (20) Niwa, R.; Shoji-Hosaka, E.; Sakurada, M.; Shinkawa, T.; Uchida, K.; Nakamura, K.; Matsushima, K.; Ueda, R.; Hanai, N.; Shitara, K. *Cancer Res.* **2004**, *64*, 2127–2133.
- (21) Kanda, Y.; Yamada, T.; Mori, K.; Okazaki, A.; Inoue, M.; Kitajima-Miyama, K.; Kuni-Kamochi, R.; Nakano, R.; Yano, K.; Kakita, S.; Shitara, K.; Satoh, M. *Glycobiology* **2007**, *17*, 104–118.
- (22) Ferrara, C.; Stuart, F.; Sonderrmann, P.; Brunker, P.; Umana, P. *J. Biol. Chem.* **2006**, *281*, 5032–5036.
- (23) Kaneko, Y.; Nimmerjahn, F.; Ravetch, J. V. *Science* **2006**, *313*, 670–673.
- (24) Anthony, R. M.; Nimmerjahn, F.; Ashline, D. J.; Reinhold, V. N.; Paulson, J. C.; Ravetch, J. V. *Science* **2008**, *320*, 373–376.
- (25) Anthony, R. M.; Wermeling, F.; Karlsson, M. C.; Ravetch, J. V. *Proc. Natl. Acad. Sci. U.S.A.* **2008**, *105*, 19571–19578.
- (26) Umana, P.; Jean-Mairet, J.; Moudry, R.; Amstutz, H.; Bailey, J. E. *Nat. Biotechnol.* **1999**, *17*, 176–180.
- (27) Davies, J.; Jiang, L.; Pan, L. Z.; LaBarre, M. J.; Anderson, D.; Reff, M. *Biotechnol. Bioeng.* **2001**, *74*, 288–294.
- (28) Hodoniczky, J.; Zheng, Y. Z.; James, D. C. *Biotechnol. Prog.* **2005**, *21*, 1644–1652.
- (29) Yamane-Ohnuki, N.; Kinoshita, S.; Inoue-Urakubo, M.; Kusunoki, M.; Iida, S.; Nakano, R.; Wakitani, M.; Niwa, R.; Sakurada, M.; Uchida, K.; Shitara, K.; Satoh, M. *Biotechnol. Bioeng.* **2004**, *87*, 614–622.
- (30) Stanley, P.; Sundaram, S.; Tang, J.; Shi, S. *Glycobiology* **2005**, *15*, 43–53.
- (31) Cox, K. M.; Sterling, J. D.; Regan, J. T.; Gasdaska, J. R.; Frantz, K. K.; Peele, C. G.; Black, A.; Passmore, D.; Moldovan-Loomis, C.; Srinivasan, M.; Cuison, S.; Cardarelli, P. M.; Dickey, L. F. *Nat. Biotechnol.* **2006**, *24*, 1591–1597.
- (32) Li, H.; et al. *Nat. Biotechnol.* **2006**, *24*, 210–215.
- (33) Strasser, R.; Castilho, A.; Stadlmann, J.; Kunert, R.; Quendler, H.; Gattlinger, P.; Jez, J.; Rademacher, T.; Altmann, F.; Mach, L.; Steinkellner, H. *J. Biol. Chem.* **2009**, *284*, 20479–20485.
- (34) Mimura, Y.; Sonderrmann, P.; Ghirlando, R.; Lund, J.; Young, S. P.; Goodall, M.; Jefferis, R. *J. Biol. Chem.* **2001**, *276*, 45539–45547.
- (35) Watt, G. M.; Lund, J.; Levens, M.; Kolli, V. S.; Jefferis, R.; Boons, G. J. *Chem. Biol.* **2003**, *10*, 807–814.
- (36) Wei, Y.; Li, C.; Huang, W.; Li, B.; Strome, S.; Wang, L. X. *Biochemistry* **2008**, *47*, 10294–10304.

- (37) Huang, W.; Li, J.; Wang, L. X. *ChemBioChem* **2011**, *12*, 932–941.
- (38) Umekawa, M.; Li, C.; Higashiyama, T.; Huang, W.; Ashida, H.; Yamamoto, K.; Wang, L. X. *J. Biol. Chem.* **2010**, *285*, 511–521.
- (39) Schwarz, F.; Huang, W.; Li, C.; Schulz, B. L.; Lizak, C.; Palumbo, A.; Numao, S.; Neri, D.; Aebi, M.; Wang, L. X. *Nat. Chem. Biol.* **2010**, *6*, 264–266.
- (40) Huang, W.; Zhang, X.; Ju, T.; Cummings, R. D.; Wang, L. X. *Org. Biomol. Chem.* **2010**, *8*, 5224–5233.
- (41) Huang, W.; Yang, Q.; Umekawa, M.; Yamamoto, K.; Wang, L. X. *ChemBioChem* **2010**, *11*, 1350–1355.
- (42) Huang, W.; Wang, D.; Yamada, M.; Wang, L. X. *J. Am. Chem. Soc.* **2009**, *131*, 17963–17971.
- (43) Huang, W.; Li, C.; Li, B.; Umekawa, M.; Yamamoto, K.; Zhang, X.; Wang, L. X. *J. Am. Chem. Soc.* **2009**, *131*, 2214–2223.
- (44) Umekawa, M.; Huang, W.; Li, B.; Fujita, K.; Ashida, H.; Wang, L. X.; Yamamoto, K. *J. Biol. Chem.* **2008**, *283*, 4469–4479.
- (45) Ochiai, H.; Huang, W.; Wang, L. X. *J. Am. Chem. Soc.* **2008**, *130*, 13790–13803.
- (46) Rising, T. W.; Heidecke, C. D.; Moir, J. W.; Ling, Z.; Fairbanks, A. J. *Chem.—Eur. J.* **2008**, *14*, 6444–6464.
- (47) Heidecke, C. D.; Ling, Z.; Bruce, N. C.; Moir, J. W.; Parsons, T. B.; Fairbanks, A. J. *ChemBioChem* **2008**, *9*, 2045–2051.
- (48) Amin, M. N.; Huang, W.; Mizanur, R. M.; Wang, L. X. *J. Am. Chem. Soc.* **2011**, *133*, 14404–14417.
- (49) Takegawa, Y.; Deguchi, K.; Nakagawa, H.; Nishimura, S. *Anal. Chem.* **2005**, *77*, 6062–6068.
- (50) Paulsen, H. *Angew. Chem., Int. Ed. Engl.* **1990**, *29*, 823–839.
- (51) Paulsen, H.; Heume, M.; Nurnberger, H. *Carbohydr. Res.* **1990**, *200*, 127–166.
- (52) Weiss, H.; Unverzagt, C. *Angew. Chem., Int. Ed.* **2003**, *42*, 4261–4263.
- (53) Eller, S.; Schubert, R.; Gundel, G.; Seifert, J.; Unverzagt, C. *Angew. Chem., Int. Ed.* **2007**, *46*, 4173–4175.
- (54) Eller, S.; Raps, C.; Niemietz, M.; Unverzagt, C. *Tetrahedron Lett.* **2010**, *51*, 2648–2651.
- (55) Wang, P.; Zhu, J.; Yuan, Y.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2009**, *131*, 16669–16671.
- (56) Crich, D.; Dudkin, V. J. *J. Am. Chem. Soc.* **2001**, *123*, 6819–6825.
- (57) Crich, D.; Li, W.; Li, H. J. *J. Am. Chem. Soc.* **2004**, *126*, 15081–15086.
- (58) Grundler, G.; Schmidt, R. R. *Carbohydr. Res.* **1985**, *135*, 203–218.
- (59) Colon, M.; Staveski, M. M.; Davis, J. T. *Tetrahedron Lett.* **1991**, *32*, 4447–4450.
- (60) Li, B.; Zeng, Y.; Hauser, S.; Song, H.; Wang, L. X. *J. Am. Chem. Soc.* **2005**, *127*, 9692–9693.
- (61) Noguchi, M.; Tanaka, T.; Gyakushi, H.; Kobayashi, A.; Shoda, S. I. *J. Org. Chem.* **2009**, *74*, 2210–2212.
- (62) Verduyn, R.; Douwes, M.; van der Klein, P. A. M.; Möisinger, E. M.; van der Marel, G. A.; van Boom, J. H. *Tetrahedron* **1993**, *49*, 7301–7316.
- (63) Vallee, F.; Karaveg, K.; Herscovics, A.; Moremen, K. W.; Howell, P. L. *J. Biol. Chem.* **2000**, *275*, 41287–41298.
- (64) Chang, V. T.; Crispin, M.; Aricescu, A. R.; Harvey, D. J.; Nettleship, J. E.; Fennelly, J. A.; Yu, C.; Boles, K. S.; Evans, E. J.; Stuart, D. I.; Dwek, R. A.; Jones, E. Y.; Owens, R. J.; Davis, S. J. *Structure* **2007**, *15*, 267–273.
- (65) Scanlan, C. N.; Ritchie, G. E.; Baruah, K.; Crispin, M.; Harvey, D. J.; Singer, B. B.; Lucka, L.; Wormald, M. R.; Wentworth, P., Jr.; Zitzmann, N.; Rudd, P. M.; Burton, D. R.; Dwek, R. A. *J. Mol. Biol.* **2007**, *372*, 16–22.
- (66) Zhou, Q.; Shankara, S.; Roy, A.; Qiu, H.; Estes, S.; McVie-Wylie, A.; Culm-Merdek, K.; Park, A.; Pan, C.; Edmunds, T. *Biotechnol. Bioeng.* **2008**, *99*, 652–665.
- (67) Yang, Q.; Li, C.; Wei, Y.; Huang, W.; Wang, L. X. *Bioconjugate Chem.* **2010**, *21*, 875–883.
- (68) Ochiai, H.; Huang, W.; Wang, L. X. *Carbohydr. Res.* **2009**, *344*, 592–598.
- (69) Umekawa, M.; Higashiyama, T.; Koga, Y.; Tanaka, T.; Noguchi, M.; Kobayashi, A.; Shoda, S.; Huang, W.; Wang, L. X.; Ashida, H.; Yamamoto, K. *Biochim. Biophys. Acta* **2010**, *1800*, 1203–1209.
- (70) Chu, S. Y.; Vostiar, I.; Karki, S.; Moore, G. L.; Lazar, G. A.; Pong, E.; Joyce, P. F.; Szymkowski, D. E.; Desjarlais, J. R. *Mol. Immunol.* **2008**, *45*, 3926–3933.
- (71) Shields, R. L.; Namenuk, A. K.; Hong, K.; Meng, Y. G.; Rae, J.; Briggs, J.; Xie, D.; Lai, J.; Stadlen, A.; Li, B.; Fox, J. A.; Presta, L. G. *J. Biol. Chem.* **2001**, *276*, 6591–6604.
- (72) Cartron, G.; Dacheux, L.; Salles, G.; Solal-Celigny, P.; Bardos, P.; Colombat, P.; Watier, H. *Blood* **2002**, *99*, 754–758.
- (73) Johnson, P.; Glennie, M. *Semin. Oncol.* **2003**, *30*, 3–8.
- (74) Koene, H. R.; Kleijer, M.; Algra, J.; Roos, D.; von dem Borne, A. E.; de Haas, M. *Blood* **1997**, *90*, 1109–1114.
- (75) Hessel, A. J.; Hangartner, L.; Hunter, M.; Havenith, C. E.; Beurskens, F. J.; Bakker, J. M.; Lanigan, C. M.; Landucci, G.; Forthall, D. N.; Parren, P. W.; Marx, P. A.; Burton, D. R. *Nature* **2007**, *449*, 101–104.
- (76) Fujita, K.; Tanaka, N.; Sano, M.; Kato, I.; Asada, Y.; Takegawa, K. *Biochem. Biophys. Res. Commun.* **2000**, *267*, 134–138.
- (77) Ren, T.; Liu, D. *Tetrahedron Lett.* **1999**, *40*, 7621–7625.
- (78) Heng, L.; Ning, J.; Kong, F. *Carbohydr. Res.* **2001**, *331*, 431–437.